1
|
Berthelsen DB, Simon LS, Ioannidis JPA, Voshaar M, Richards P, Goel N, Strand V, Nielsen SM, Shea BJ, Tugwell P, Bartlett SJ, Hazlewood GS, March L, Singh JA, Suarez-Almazor ME, Boers M, Stevens RM, Furst DE, Woodworth T, Leong A, Brooks PM, Flurey C, Christensen R. Stakeholder endorsement advancing the implementation of a patient-reported domain for harms in rheumatology clinical trials: Outcome of the OMERACT Safety Working Group. Semin Arthritis Rheum 2023; 63:152288. [PMID: 37918049 DOI: 10.1016/j.semarthrit.2023.152288] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/25/2023] [Revised: 10/16/2023] [Accepted: 10/24/2023] [Indexed: 11/04/2023]
Abstract
OBJECTIVES To develop an understanding of the concept of safety/harms experienced by patients involved in clinical trials for their rheumatic and musculoskeletal diseases (RMDs) and to seek input from the OMERACT community before moving forward to developing or selecting an outcome measurement instrument. METHODS OMERACT 2023 presented and discussed interview results from 34 patients indicating that up to 171 items might be important for patients' harm-reporting. RESULTS Domain was defined in detail and supported by qualitative work. Participants in the Special-Interest-Group endorsed (96 %) that enough qualitative data are available to start Delphi survey(s). CONCLUSION We present a definition of safety/harms that represents the patient voice (i.e., patients' perception of safety) evaluating the symptomatic treatment-related adverse events for people with RMDs enrolled in clinical trials.
Collapse
Affiliation(s)
- Dorthe B Berthelsen
- Section for Biostatistics and Evidence-Based Research, the Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark; Research Unit of Rheumatology, Department of Clinical Research, University of Southern Denmark, Odense University Hospital, Denmark; Department of Rehabilitation, Municipality of Guldborgsund, Nykoebing F, Denmark
| | | | - John P A Ioannidis
- Departments of Medicine, Epidemiology and Population Health, Biomedical Data Science, and Statistics, and Meta-Research Innovation Center at Stanford (METRICS), Stanford University, California, USA
| | - Marieke Voshaar
- Department of Pharmacy, Sint Maartenskliniek, Department of Pharmacy, RadboudUMC, Nijmegen, the Netherlands
| | - Pam Richards
- Department of Rheumatology, University of Bristol, Bristol, United Kingdom
| | - Niti Goel
- Division of Rheumatology, Duke University School of Medicine, Durham, NC, USA
| | - Vibeke Strand
- Division of Immunology/Rheumatology, Stanford University, Palo Alto CA, USA
| | - Sabrina M Nielsen
- Section for Biostatistics and Evidence-Based Research, the Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark; Research Unit of Rheumatology, Department of Clinical Research, University of Southern Denmark, Odense University Hospital, Denmark
| | - Beverly J Shea
- Ottawa Hospital Research Institute, Clinical Epidemiology Program and School of Epidemiology and Public Health, University of Ottawa, Canada
| | - Peter Tugwell
- Department of Medicine, School of Epidemiology, Public Health and Community Medicine, University of Ottawa, Canada
| | | | - Glen S Hazlewood
- Department of Medicine, Cumming School of Medicine, University of Calgary; Department of Community Health Sciences, Cumming School of Medicine, University of Calgary; Arthritis Research Canada
| | - Lyn March
- Department of Rheumatology, Royal North Shore Hospital, Kolling Institue and The University of Sydney, Sydney, Australia
| | - Jasvinder A Singh
- Medicine Service, VA Medical Center, Birmingham, AL, USA; Department of Medicine and the School of Medicine, University of Alabama at Birmingham (UAB), Birmingham, AL, USA; Department of Epidemiology and the UAB School of Public Health, Birmingham, AL, USA
| | - Maria E Suarez-Almazor
- Department of Health Services Research and Section of Rheumatology and Clinical Immunology, University of Texas MD Anderson Cancer Centre, Houston, TX, USA
| | - Maarten Boers
- Department of Epidemiology and Data Science, Amsterdam UMC, Vrije Universiteit, Amsterdam, the Netherlands
| | | | - Daniel E Furst
- David Geffen School of Med. Department of Medicine, Division of Rheumatology, UCLA, Los Angeles, California, USA
| | - Thasia Woodworth
- David Geffen School of Med. Department of Medicine, Division of Rheumatology, UCLA, Los Angeles, California, USA
| | - Amye Leong
- Healthy Motivation, Santa Barbara, California USA
| | - Peter M Brooks
- Centre for Health Policy Melbourne School of Population and Global Health University of Melbourne, Australia
| | - Caroline Flurey
- Faculty of Health and Applied Sciences, University of the West of England, Bristol, United Kingdom
| | - Robin Christensen
- Section for Biostatistics and Evidence-Based Research, the Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark; Research Unit of Rheumatology, Department of Clinical Research, University of Southern Denmark, Odense University Hospital, Denmark.
| |
Collapse
|
2
|
Bridgewater S, Shepherd MA, Dawson J, Richards P, Silverthorne C, Ndosi M, Almeida C, Black RJ, Cheah JTL, Dures E, Ghosh N, Hoon EA, Lyne S, Navarro-Millan I, Pearce-Fisher D, Ruediger C, Tieu J, Yip K, Mackie S, Goodman S, Hill C, Robson J. POS0040-HPR PATIENT PERCEPTIONS OF IMPACT OF GLUCOCORTICOID THERAPY IN THE RHEUMATIC DISEASES: INTERNATIONAL DEVELOPMENT OF A TREATMENT-SPECIFIC PATIENT REPORTED OUTCOME MEASURE. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.1479] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BackgroundGlucocorticoids (GCs) are a key treatment for inflammatory rheumatic diseases, but they cause a wide range of adverse side-effects which are of concern both to patients and clinicians.ObjectivesThe objective of this study was to explore the impact of GC therapy on health-related quality of life (HRQoL) during treatment for rheumatic diseases, as a basis for development of a Patient-Reported Outcome Measure (PROM) to be used in clinical trials and practice.MethodsPatients from the UK, USA and Australia who were treated with GCs in the last two years for a rheumatic condition were invited to take part in semi-structured qualitative interviews. Purposive sampling was used to include participants with a range of demographic and disease features. A steering committee of patient research partners, clinicians and methodologists devised an initial conceptual framework, which informed interview prompts and cues. Interviews were carried out by experienced qualitative researchers who encouraged participants to tell their stories and talk about the effects, both adverse and beneficial, of their experiences and perceptions of treatment with GCs, to identify salient physical and psychological symptoms and aspects of HRQoL. The interview data were organised using NVivo, and inductive analysis identified initial themes and domains. Candidate questionnaire items were developed and refined using cognitive interviewing, linguistic assessment, and input from patient research partners.ResultsSixty semi-structured qualitative interviews were conducted (UK n=34, USA n=10, Australia n=16). Mean participant age was 58 years; 39 (66.1%) were female. Purposive sampling of participants provided a broad range of demographic features, GC dosages and inflammatory rheumatic conditions, with 27% having connective tissue disease, 25% inflammatory arthritis, 30% systemic vasculitis and 16% other rheumatic conditions.Initial domains were developed to identify key themes relating to treatment using GCs and their impact on HRQoL; see Figure 1.Figure 1.Steroid PRO Initial ThemesA long-list of 134 initial candidate questionnaire items was developed from the individual themes. These items were reviewed by a qualitative working group of patient research partners, researchers and clinicians to reduce duplication and ambiguity of items. The resulting 62 items were tested and refined by piloting with patient research partners, iterative rounds of cognitive interviews with patients with a range of rheumatic conditions from the UK, USA and Australia, and a linguistic translatability assessment, to define a draft questionnaire of 40 items.ConclusionThis international qualitative study underpins the development of candidate items for a treatment-specific PROM for patients with rheumatic diseases. The draft questionnaire is currently being tested in an online large-scale survey to determine the final scale structure and measurement properties using Rasch analysis, factor analysis, test-retest, comparison with EQ5D, and known groups analysis.Disclosure of InterestsSusan Bridgewater Grant/research support from: Vifor Pharma, Michael A Shepherd Grant/research support from: Vifor Pharma, Jill Dawson: None declared, Pamela Richards: None declared, Christine Silverthorne: None declared, Mwidimi Ndosi: None declared, Celia Almeida: None declared, Rachel J Black: None declared, Jonathan T.L. Cheah: None declared, Emma Dures: None declared, Nilasha Ghosh: None declared, Elizabeth A Hoon: None declared, Suellen Lyne: None declared, Iris Navarro-Millan Consultant of: Honorarium on Swedish Orpham Biovitrum (SOBI) advisory board 2021, Diyu Pearce-Fisher: None declared, Carlee Ruediger: None declared, Joanna Tieu: None declared, Kevin Yip: None declared, Sarah Mackie: None declared, Susan Goodman: None declared, Catherine Hill: None declared, Joanna Robson Speakers bureau: EULAR Symposium 2021 for Vifor Pharma, Consultant of: Honorarium for Vifor Pharma advisory board 2021, Grant/research support from: Vifor Pharma 2020-2022
Collapse
|
3
|
Blundell R, Richards P. The Forensic Pathology of the Sexual Abuse of a Group of Chickens. J Comp Pathol 2022. [DOI: 10.1016/j.jcpa.2021.11.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
4
|
Howell S, Krebs M, Lord S, Kenny L, Bahl A, Clack G, Ainscow E, Arkenau HT, Mansi J, Palmieri C, Richards P, Jeselsohn R, Mitri Z, Gradishar W, Sardesai S, O'Shaughnessy J, Lehnert M, Ali S, McIntosh S, Coombes R. 265P Study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in combination with fulvestrant in patients with advanced hormone receptor positive HER2 negative breast cancer (HR+BC). Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.548] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
5
|
Campion T, Maity A, Ali S, Richards P, Adams A. Concurrent thyrolipomatosis and thymolipoma in a patient with myasthenia gravis: a case report and review of the literature. Ann R Coll Surg Engl 2021; 103:e212-e215. [PMID: 34192501 PMCID: PMC10752004 DOI: 10.1308/rcsann.2020.7089] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 09/07/2020] [Indexed: 11/22/2022] Open
Abstract
We present a case of a man with a background of myasthenia gravis who presented with a neck lump, which was diagnosed as thyrolipomatosis in continuity with a very large thymolipoma. Following removal of these lesions, the patient's myaesthenic symptoms improved. While thymolipomas are often seen in the context of myasthenia gravis, thyrolipomatosis is a rare entity and to our knowledge the concurrent finding of both lesions with myasthenia gravis has never been reported. We highlight the important imaging features of both entities and the clinical importance of recognising them.
Collapse
Affiliation(s)
| | - A Maity
- Royal London Hospital,
London, UK
| | - S Ali
- Royal London Hospital,
London, UK
| | | | - A Adams
- Royal London Hospital,
London, UK
| |
Collapse
|
6
|
Sweeney AMT, Robson J, Flurey C, Richards P, Mccabe C, Ndosi M. POS0158-HPR UNDERSTANDING NURSE-LED CARE IN EARLY RA: INTERVIEW STUDY WITH RHEUMATOLOGY NURSE SPECIALISTS. Ann Rheum Dis 2021. [DOI: 10.1136/annrheumdis-2021-eular.555] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:Nurse-led care in early RA is not well defined in the literature and the current recommendations.Objectives:This study aimed to develop an understanding of what comprises nurse-led care in early RA from the perspective of rheumatology nurse specialists.Methods:This was a qualitative study using semi-structured telephone interviews with rheumatology nurse specialists in England (Summer 2020). Interviews were audio-recorded, transcribed verbatim and analysed using inductive thematic analysis.[1]Results:Sixteen nurses were recruited and interviews lasted between 30 to 60 minutes. Seven themes were identified.Early disease managementCare was characterised by evidence-based RA management provided by experienced nurse specialists with a high degree of autonomy, in the context of a rheumatology multidisciplinary team. The aims of care were to: start treatment, keep in treatment, educate and support.’So treat to target...escalating treatment as necessary, and addressing any concerns that the patients might have’ (CNS14)Addressing psychosocial needsPatients with early RA experience shock, fear, anger, grief and denial while feeling unwell with pain and fatigue. Nurses use a holistic, person-centred and empathetic approach to address psychosocial needs, building a working relationship, listening and creating trust.’Because it all relates, and if they’re stressed because they’re not coping at work, then their arthritis isn’t going to be so good. So everything relates to one another really’ (CNS06)Monitoring treatment, disease impact and patient outcomesNurses monitor disease activity and disease impact using validated outcome measures and by asking questions during the consultation. Good outcomes are disease control, managing disease impact, medication and side effects, wellbeing and keeping in work.’When you get them stable, when you get them into remission, when they’re happy, when they’re feeling well, I think there’s lots of ways you can measure that’… (CNS13)Coordinating care, referring and signpostingNurses coordinate care, refer to other health professionals and signpost patients to relevant services and charities. Lack of access to psychology expertise was highlighted.‘And whilst most of us have got some degree of understanding of…self management, or psychology…we’re not psychologists’ (CNS02)Providing a ‘lifeline’Nurse-led telephone advice services provide a ‘lifeline’ for patients. If patients struggle, they can call and speak with a specialist who knows them and their RA well.’The advice line has been a lifeline to them, to be able to speak to someone, to be able to get a response quickly to their questions, they feel very well supported, they know that they can always call us’ (CNS16)Service evaluation and auditingThe individual clinics are reviewed regularly. Patients are asked for feedback on their experience of appointments, if their needs were met and about changes to the service....‘It’s really important to ask them initially what they expect to have from the consultation...We’ve always had really good feedback in general’… (CNS02)COVID-19 challenges and opportunitiesThe pandemic caused major disruptions to the services, prohibiting most face-to-face consultations which was an essential aspect of clinical assessments. Despite the challenges imposed by the pandemic, the services adapted fast, using telephone, video clinics and digital solutions, which streamlined procedures and improved documentation and communication.‘I do have to rely on them telling me what’s going on, because I can’t see it at the moment’ (CNS14)’With Covid we’re doing it over the telephone, and we’re getting them to watch the video [injection tutorial] before we have the appointment with them’ (CNS04)Conclusion:Nurse-led care in early arthritis is a specialist service, addressing complex needs of patients, using evidence based and person-centred approaches. Innovation and service improvement are seen as part of the role.References:[1]Braun V, Clarke V. Successful Qualitative Research. First edition. London: SAGE 2013.Disclosure of Interests:None declared
Collapse
|
7
|
Bridgewater S, Dawson J, Ndosi M, Black RJ, Cheah JTL, Dures E, Ghosh N, Hoon EA, Navarro-Millan I, Pearce-Fisher D, Richards P, Ruediger C, Silverthorne C, Tieu J, Mackie S, Goodman S, Hill C, Robson J. AB0834 DEVELOPMENT OF A CONCEPTUAL FRAMEWORK FOR A PATIENT REPORTED OUTCOME MEASURE TO CAPTURE PATIENTS’ PERCEPTIONS OF GLUCOCORTICOID THERAPY DURING TREATMENT FOR RHEUMATIC DISEASES. Ann Rheum Dis 2021. [DOI: 10.1136/annrheumdis-2021-eular.164] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:Glucocorticoids (GCs) are a key treatment for the autoimmune rheumatic diseases; however, they produce numerous physical and psychological side effects.1 The Outcome Measures in Rheumatology (OMERACT) Glucocorticoid Working Group have identified that there are no Patient Reported Outcome Measures (PROMs) for assessing the impact of systemic GC therapy across multiple rheumatic diseases from the patient’s perspective.2,3Objectives:The aim is to explore the impact of GCs on the symptoms and health-related quality of life of adults with rheumatic inflammatory diseases, to inform items for inclusion in a PROM. Key considerations will include patient perceptions of GC therapy at diagnosis and over the course of treatment, for use in future randomised controlled trials or in clinical practice.Methods:An international steering committee comprising researchers, rheumatology clinicians, methodologists and patient partners in the UK, Australia and USA developed an initial conceptual framework informed by a review of the literature. Semi-structured interviews were conducted in each country with patients who had an autoimmune rheumatic disease and had received GC therapy. The interviews explored salient aspects of health-related quality of life associated with being treated with GCs.Results:Interviews have been completed in three continents with patients who had a range of demographic features, rheumatological conditions and duration and dosage of GC therapy. Figure 1 shows the initial conceptual framework for developing the GC PROM (Steroid PRO).Figure 1.Conclusion:This conceptual framework will act as an evolving guide in the development of a PROM for assessing patients’ perspectives of systemic glucocorticoid therapy. Future work will include inductive analysis of qualitative transcripts to inform candidate questionnaire items, cognitive interviewing, linguistic translatability assessment, and an international validation survey to define the final PROM questionnaire and its measurement properties.References:[1]Cheah JTL, Robson JC, Black RJ, et al. The patient’s perspective of the adverse effects of glucocorticoid use: A systematic review of quantitative and qualitative studies. From an OMERACT working group. Semin Arthritis Rheum. 2020 Oct; 50(5):996-1005.[2]Black RJ, Robson JC, Goodman SM, et al. A Patient-reported Outcome Measure for Effect of Glucocorticoid Therapy in Adults with Inflammatory Diseases Is Needed: Report from the OMERACT 2016 Special Interest Group. J Rheumatol. 2017; 44(11):1754-8.[3]Cheah JTL, Black RJ, Robson JC, et al. Toward a Core Domain Set for Glucocorticoid Impact in Inflammatory Rheumatic Diseases: The OMERACT 2018 Glucocorticoid Impact Working Group. J Rheumatol. 2019; 46(9):1179-1182.Disclosure of Interests:Susan Bridgewater Grant/research support from: Grant from Vifor Pharma for an independent investigator-led study to develop a PRO for steroids, Jill Dawson: None declared, Mwidimi Ndosi: None declared, Rachel J Black: None declared, Jonathan T.L. Cheah: None declared, Emma Dures: None declared, Nilasha Ghosh: None declared, Elizabeth A Hoon: None declared, Iris Navarro-Millan Consultant of: Received consultant fees from SOBI, Diyu Pearce-Fisher: None declared, Pamela Richards: None declared, Carlee Ruediger: None declared, Christine Silverthorne: None declared, Joanna Tieu Grant/research support from: Vifor Pharma, Sarah Mackie Consultant of: Consultancy on behalf of institution for Roche/Chugai, Sanofi, AbbVie and AstraZeneca, Grant/research support from: Educational grant from Roche to attend EULAR2019, Susan Goodman: None declared, Catherine Hill: None declared, Joanna Robson Speakers bureau: Vifor Pharma for educational webinar, Grant/research support from: Grant from Vifor Pharma for an independent investigator-led study to develop a PRO for steroids
Collapse
|
8
|
Wyld L, Reed MWR, Collins K, Burton M, Lifford K, Edwards A, Ward S, Holmes G, Morgan J, Bradburn M, Walters SJ, Ring A, Robinson TG, Martin C, Chater T, Pemberton K, Shrestha A, Nettleship A, Murray C, Brown M, Richards P, Cheung KL, Todd A, Harder H, Brain K, Audisio RA, Wright J, Simcock R, Armitage F, Bursnall M, Green T, Revell D, Gath J, Horgan K, Holcombe C, Winter M, Naik J, Parmeshwar R, Gosney M, Hatton M, Thompson AM. Bridging the age gap in breast cancer: cluster randomized trial of two decision support interventions for older women with operable breast cancer on quality of life, survival, decision quality, and treatment choices. Br J Surg 2021; 108:499-510. [PMID: 33760077 PMCID: PMC10364907 DOI: 10.1093/bjs/znab005] [Citation(s) in RCA: 15] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2020] [Revised: 10/04/2020] [Accepted: 12/28/2020] [Indexed: 11/14/2022]
Abstract
BACKGROUND Rates of surgery and adjuvant therapy for breast cancer vary widely between breast units. This may contribute to differences in survival. This cluster RCT evaluated the impact of decision support interventions (DESIs) for older women with breast cancer, to ascertain whether DESIs influenced quality of life, survival, decision quality, and treatment choice. METHODS A multicentre cluster RCT compared the use of two DESIs against usual care in treatment decision-making in older women (aged at least ≥70 years) with breast cancer. Each DESI comprised an online algorithm, booklet, and brief decision aid to inform choices between surgery plus adjuvant endocrine therapy versus primary endocrine therapy, and adjuvant chemotherapy versus no chemotherapy. The primary outcome was quality of life. Secondary outcomes included decision quality measures, survival, and treatment choice. RESULTS A total of 46 breast units were randomized (21 intervention, 25 usual care), recruiting 1339 women (670 intervention, 669 usual care). There was no significant difference in global quality of life at 6 months after the baseline assessment on intention-to-treat analysis (difference -0.20, 95 per cent confidence interval (C.I.) -2.69 to 2.29; P = 0.900). In women offered a choice of primary endocrine therapy versus surgery plus endocrine therapy, knowledge about treatments was greater in the intervention arm (94 versus 74 per cent; P = 0.003). Treatment choice was altered, with a primary endocrine therapy rate among women with oestrogen receptor-positive disease of 21.0 per cent in the intervention versus 15.4 per cent in usual-care sites (difference 5.5 (95 per cent C.I. 1.1 to 10.0) per cent; P = 0.029). The chemotherapy rate was 10.3 per cent at intervention versus 14.8 per cent at usual-care sites (difference -4.5 (C.I. -8.0 to 0) per cent; P = 0.013). Survival was similar in both arms. CONCLUSION The use of DESIs in older women increases knowledge of breast cancer treatment options, facilitates shared decision-making, and alters treatment selection. Trial registration numbers: EudraCT 2015-004220-61 (https://eudract.ema.europa.eu/), ISRCTN46099296 (http://www.controlled-trials.com).
Collapse
Affiliation(s)
- L Wyld
- Department of Oncology and Metabolism, University of Sheffield Medical School, Sheffield, UK
| | - M W R Reed
- Brighton and Sussex Medical School, Falmer, Brighton, UK
| | - K Collins
- College of Health, Wellbeing and Life Sciences, Department of Allied Health Professions, Sheffield Hallam University, Sheffield, UK
| | - M Burton
- College of Health, Wellbeing and Life Sciences, Department of Allied Health Professions, Sheffield Hallam University, Sheffield, UK
| | - K Lifford
- Division of Population Medicine, Cardiff University, Cardiff, UK
| | - A Edwards
- Division of Population Medicine, Cardiff University, Cardiff, UK
| | - S Ward
- Department of Health Economics and Decision Science, School for Health and Related Research, ScHARR, University of Sheffield, Sheffield, UK
| | - G Holmes
- Department of Health Economics and Decision Science, School for Health and Related Research, ScHARR, University of Sheffield, Sheffield, UK
| | - J Morgan
- Department of Oncology and Metabolism, University of Sheffield Medical School, Sheffield, UK
| | - M Bradburn
- Clinical Trials Research Unit, School for Health and Related Research, University of Sheffield, Sheffield, UK
| | - S J Walters
- Clinical Trials Research Unit, School for Health and Related Research, University of Sheffield, Sheffield, UK
| | - A Ring
- Royal Marsden Hospital NHS Foundation Trust, London, UK
| | - T G Robinson
- Department of Cardiovascular Sciences and NIHR Biomedical Research Centre, University of Leicester, Cardiovascular Research Centre, Glenfield General Hospital, Leicester, UK
| | - C Martin
- Department of Oncology and Metabolism, University of Sheffield Medical School, Sheffield, UK
| | - T Chater
- Clinical Trials Research Unit, School for Health and Related Research, University of Sheffield, Sheffield, UK
| | - K Pemberton
- Clinical Trials Research Unit, School for Health and Related Research, University of Sheffield, Sheffield, UK
| | - A Shrestha
- Department of Oncology and Metabolism, University of Sheffield Medical School, Sheffield, UK
| | - A Nettleship
- EpiGenesys, University of Sheffield, Sheffield, UK
| | - C Murray
- EpiGenesys, University of Sheffield, Sheffield, UK
| | - M Brown
- EpiGenesys, University of Sheffield, Sheffield, UK
| | - P Richards
- Department of Health Economics and Decision Science, School for Health and Related Research, ScHARR, University of Sheffield, Sheffield, UK
| | - K L Cheung
- University of Nottingham, Royal Derby Hospital, Derby, UK
| | - A Todd
- Department of Oncology and Metabolism, University of Sheffield Medical School, Sheffield, UK
| | - H Harder
- Brighton and Sussex Medical School, Falmer, Brighton, UK
| | - K Brain
- Division of Population Medicine, Cardiff University, Cardiff, UK
| | - R A Audisio
- University of Gothenberg, Sahlgrenska Universitetssjukhuset, Gothenberg, Sweden
| | - J Wright
- Brighton and Sussex Medical School, Falmer, Brighton, UK
| | - R Simcock
- Brighton and Sussex Medical School, Falmer, Brighton, UK
| | | | - M Bursnall
- Clinical Trials Research Unit, School for Health and Related Research, University of Sheffield, Sheffield, UK
| | - T Green
- Yorkshire and Humber Consumer Research Panel (yhcrp.org.uk), Leeds, UK
| | - D Revell
- Yorkshire and Humber Consumer Research Panel (yhcrp.org.uk), Leeds, UK
| | - J Gath
- Yorkshire and Humber Consumer Research Panel (yhcrp.org.uk), Leeds, UK
| | - K Horgan
- Department of Breast Surgery, Bexley Cancer Centre, St James's University Hospital, Leeds, UK
| | - C Holcombe
- Liverpool University Hospitals Foundation Trust, Liverpool, UK
| | - M Winter
- Weston Park Hospital, Sheffield, UK
| | - J Naik
- Pinderfields Hospital, Mid Yorkshire NHS Foundation Trust, Wakefield, UK
| | - R Parmeshwar
- University Hospitals of Morecambe Bay, Lancaster, UK
| | - M Gosney
- Royal Berkshire NHS Foundation Trust, Reading, UK
| | - M Hatton
- Weston Park Hospital, Sheffield, UK
| | - A M Thompson
- Department of Surgery, Baylor College of Medicine, Houston, Texas, USA
| |
Collapse
|
9
|
Duncan JS, Angell JW, Richards P, Lenzi L, Staton GJ, Grove-White D, Clegg S, Oikonomou G, Carter SD, Evans NJ. The dysbiosis of ovine foot microbiome during the development and treatment of contagious ovine digital dermatitis. Anim Microbiome 2021; 3:19. [PMID: 33597028 PMCID: PMC7888161 DOI: 10.1186/s42523-021-00078-4] [Citation(s) in RCA: 16] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2020] [Accepted: 01/15/2021] [Indexed: 12/19/2022] Open
Abstract
BACKGROUND Contagious Ovine Digital Dermatitis (CODD) is an emerging and common infectious foot disease of sheep which causes severe welfare and economic problems for the sheep industry. The aetiology of the disease is not fully understood and control of the disease is problematic. The aim of this study was to investigate the polybacterial aetiopathogenesis of CODD and the effects of antibiotic treatment, in a longitudinal study of an experimentally induced disease outbreak using a 16S rRNA gene amplicon sequencing approach. RESULTS CODD was induced in 15/30 experimental sheep. During the development of CODD three distinct phenotypic lesion stages were observed. These were an initial interdigital dermatitis (ID) lesion, followed by a footrot (FR) lesion, then finally a CODD lesion. Distinct microbiota were observed for each lesion in terms of microbial diversity, clustering and composition. Porphyromonadaceae, Family XI, Veillonellaceae and Fusobacteriaceae were significantly associated with the diseased feet. Veillonellaceae and Fusobacteriaceae were most associated with the earlier stages of ID and footrot rather than CODD. Following antibiotic treatment of the sheep, the foot microbiota showed a strong tendency to return to the composition of the healthy state. The microbiota composition of CODD lesions collected by swab and biopsy methods were different. In particular, the Spirochaetaceae family were more abundant in samples collected by the biopsy method, suggesting that these bacteria are present in deeper tissues of the diseased foot. CONCLUSION In this study, CODD presented as part of a spectrum of poly-bacterial foot disease strongly associated with bacterial families Porphyromonadaceae, Family XI (a family in Clostridiales also known as Clostridium cluster XI), Veillonellaceae and Fusobacteriaceae which are predominately Gram-negative anaerobes. Following antibiotic treatment, the microbiome showed a strong tendency to return to the composition of the healthy state. The composition of the healthy foot microbiome does not influence susceptibility to CODD. Based on the data presented here and that CODD appears to be the severest end stage of sheep infectious foot disease lesions, better control of the initial ID and FR lesions would enable better control of CODD and enable better animal welfare.
Collapse
Affiliation(s)
- J. S. Duncan
- Department of Livestock and One Health, Institute of Infection, Veterinary and Ecological Science, University of Liverpool, Leahurst Campus, Neston, Wirral CH64 7TE UK
| | - J. W. Angell
- Wern Veterinary Surgeons, Department of Research and Innovation, Unit 11, Lon Parcwr Industrial Estate, Ruthin, LL15 1NJ UK
| | - P. Richards
- Department of Veterinary Pathology, Institute of Infection, Veterinary and Ecological Science, University of Liverpool, Leahurst Campus, Neston, Wirral CH64 7TE UK
| | - L. Lenzi
- Centre for Genomic Research, Department of Evolution, Ecology and Behaviour, Institute of Infection, Veterinary and Ecological Science, University of Liverpool, Liverpool, L69 7ZB UK
| | - G. J. Staton
- Department of Infection Biology & Microbiomes, Institute of Infection, Veterinary and Ecological Science, The University of Liverpool, Leahurst Campus, Neston, Wirral CH64 7TE UK
| | - D. Grove-White
- Department of Livestock and One Health, Institute of Infection, Veterinary and Ecological Science, University of Liverpool, Leahurst Campus, Neston, Wirral CH64 7TE UK
| | - S. Clegg
- School of Life Sciences, College of Science, University of Lincoln, Brayford Pool Campus, Lincoln, LN6 7TS UK
| | - G. Oikonomou
- Department of Livestock and One Health, Institute of Infection, Veterinary and Ecological Science, University of Liverpool, Leahurst Campus, Neston, Wirral CH64 7TE UK
| | - S. D. Carter
- Department of Infection Biology & Microbiomes, Institute of Infection, Veterinary and Ecological Science, The University of Liverpool, Leahurst Campus, Neston, Wirral CH64 7TE UK
| | - N. J. Evans
- Department of Infection Biology & Microbiomes, Institute of Infection, Veterinary and Ecological Science, The University of Liverpool, Leahurst Campus, Neston, Wirral CH64 7TE UK
| |
Collapse
|
10
|
Wyld L, Reed M, Collins K, Burton M, Lifford K, Edwards A, Ward S, Holmes G, Morgan J, Bradburn M, Walters S, Ring A, Martin C, Shrestha A, Nettleship A, Brown M, Richards P, Todd A, Harder H, Brain K. Cluster randomised trial to evaluate the clinical benefits of decision support interventions for older women with operable breast cancer. Eur J Cancer 2020. [DOI: 10.1016/s0959-8049(20)30545-1] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
11
|
Sweeney AMT, Mccabe C, Flurey C, Robson J, Berry A, Richards P, Ndosi M. SAT0643-HPR NURSE-LED CARE FROM THE PERSPECTIVE OF PEOPLE WITH EARLY RHEUMATOID ARTHRITIS: A QUALITATIVE SYSTEMATIC REVIEW. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.502] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:Nurse-led care has been shown to be clinically effective and cost effective in rheumatoid arthritis (RA) but the role of the nurse in early RA is not well defined. Evidence for processes of care in RA is limited and it is not known how well rheumatology nurse-led clinics meet care needs of people with early RA.Objectives:The aim of this study was to develop an understanding of rheumatology nurse-led care from the perspective of people with early RA.Methods:A qualitative systematic review was conducted. The review protocol is published in the International prospective register of systematic reviews.In March 2019, the following databases were searched: MEDLINE, EMBASE, CINAHL, PsycINFO and OpenGrey. Due to lack of studies in early RA this review included adults with early and established inflammatory arthritis, qualitative studies with data on patients’ perspectives of nurse-led care, published in peer-reviewed journals in English between 2010 and 2019. Two reviewers screened titles, abstracts and full texts. Data were extracted and managed in tables. Joanna Briggs Institute Critical Appraisal Checklist was used for quality assessment of the included studies. A thematic synthesis was undertaken using the framework of Thomas and Harden.1Results:The search identified 1034 records. After screening and assessing for eligibility, 8 qualitative studies were included in the review (133 patients), 2 studies included people with early RA. Three main themes were identified (Figure 1).Figure 1.Themes of nurse-led care from the perspective of people with RAProviding knowledge and skill. This theme delineated rheumatology nursing as providing professional expertise in the planning and delivery of care. The rheumatology nurse-led service included easy access via telephone helpline, consultations with the clinical nurse specialist for assessment of disease activity and care needs, planning of care, disease information and education, supporting self-management, and referral to rheumatologist and the multi-disciplinary team. People with RA highly valued the nurse expertise and specialist knowledge provided at nurse-led clinics.‘She was very good at informing me, so I have only praise for this ... because I have never had it like this before’. (Person with early RA).Using a person-centred approach.This theme showed nurse-led care using a person-centred approach combined with empathy and good communication skills, which created a good therapeutic environment. People with RA appreciated the person-centeredness, empathy and involvement of the nurse. ‘She is very sensitive. She can see if I am feeling bad and comes straight to me and asks: “How are you today?” ...You are treated and taken seriously’. (Person with early RA).Meeting patients‘ care needs. This theme presented nurse-led care as creating a sense of being empowered and psychologically supported in the management of RA and its impact. Nurse-led care made people with RA feel cared for, secure and confident. It added value to rheumatology care and made care complete.‘The thought of sticking a needle into my own stomach... it felt a bit like I would never manage to do that. However, they have been absolutely wonderful here ... and now I can do it myself’. (Person with early RA).Conclusion:Nurse-led care for people with RA is characterised by provision of rheumatology expertise using a person-centred approach, and patients‘ holistic care needs are being met. This study found a dearth of literature on perceptions of nurse-led care in people with early RA, which highlights the need for further research in this population.References:[1]Thomas J, Harden A. Methods for the thematic synthesis of qualitative research in systematic reviews.BMC Med Res Methodol2008; 8: 45.Disclosure of Interests:Anne-Marie Tetsche Sweeney: None declared, Candy McCabe: None declared, Caroline Flurey: None declared, Joanna Robson: None declared, Alice Berry: None declared, Pamela Richards: None declared, Mwidimi Ndosi Grant/research support from: Bristol Myers Squibb, Consultant of: Janssen, Pfizer
Collapse
|
12
|
Tanner JT, Barnett SA, Mountford MK, Barnett S, Beare-Rogers JL, Bueno MP, DeAngelis N, deVries EJ, DeVries JW, Dube D, Ellefson W, Landen WO, Navis J, Pearson D, Reynolds SL, Richards P, Soliman AG, Thomson W. Analysis of Milk-Based Infant Formula. Phase IV. Iodide, Linoleic Acid, and Vitamins D and K: U.S. Food and Drug Administration-Infant Formula Council: Collaborative Study. J AOAC Int 2020. [DOI: 10.1093/jaoac/76.5.1042] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
Abstract
In 1982, the U.S. Food and Drug Administration, the Infant Formula Council and its member companies, contract laboratories, and other government laboratories began a study of analytical methods for the nutrients listed in the Infant Formula Act of 1980. Phases I, II, III, and V have been completed. The present report provides data on Phase IV, in which 13 laboratories collaboratively studied an ion-selective electrode method for analyzing iodide, a gas chromatographic method for linoleic acid, and 2 liquid chromatographic (LC) methods each for vitamins D and K. Data were insufficient to evaluate one each of the LC methods studied for vitamins K and D. The relative standard deviations (RSD) are sufficient for the nutrient levels found in infant formula. RSDs (%) for repeatability (RSDr) and reproducibility (RSDR), respectively, were as follows: iodide, 4.0-11.4 and 13.5-18.2; linoleic acid, 1.0-1.6 and 3.5-5.1; vitamin K1, 3.2-16.0 and 6.2-19.4; and vitamin D3,4.2 and 35.0. The recommendation to adopt the method for vitamin D was supported by the results of a ministudy. All laboratories were capable of using these methods with little training. The methods for determination of iodide, linoleic acid, and vitamins D and K in ready-to-feed milkbased infant formula have been adopted first action by AOAC International.
Collapse
Affiliation(s)
- James T Tanner
- U.S. Food and Drug Administration, Division of Nutrition, Washington, DC 20204
| | | | - Mardi K Mountford
- Infant Formula Council, 5775 Peachtree-Dunwoody Rd, Atlanta, GA 30342
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Vale J, Bird K, Mayl C, Allen J, Richards P, O’Toole R, Wilson E. 16POP-UP DELIRIUM SIMULATION TRAINING. Age Ageing 2019. [DOI: 10.1093/ageing/afy211.16] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- J Vale
- Musgrove Park Hospital, Taunton and Somerset NHS Foundation Trust
| | - K Bird
- Musgrove Park Hospital, Taunton and Somerset NHS Foundation Trust
| | - C Mayl
- Musgrove Park Hospital, Taunton and Somerset NHS Foundation Trust
| | - J Allen
- Musgrove Park Hospital, Taunton and Somerset NHS Foundation Trust
| | - P Richards
- Musgrove Park Hospital, Taunton and Somerset NHS Foundation Trust
| | - R O’Toole
- Musgrove Park Hospital, Taunton and Somerset NHS Foundation Trust
| | - E Wilson
- Musgrove Park Hospital, Taunton and Somerset NHS Foundation Trust
| |
Collapse
|
14
|
Maffulli G, Del Buono A, Richards P, Oliva F, Maffulli N. Conservative, minimally invasive and open surgical repair for management of acute ruptures of the Achilles tendon: a clinical and functional retrospective study. Muscles Ligaments Tendons J 2019. [DOI: 10.32098/mltj.01.2017.07] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Affiliation(s)
- G. Maffulli
- Centre for Sports and Exercise Medicine, Barts and The London School of Medicine and Dentistry, Mile End Hospital, London, UK
| | - A. Del Buono
- Department of Orthopaedic and Trauma Surgery, Campus Biomedico University of Rome, Rome, Italy
| | - P. Richards
- Department of Radiology, University Hospitals of North Midlands NHS Trust, Stoke on Trent, UK
| | - F. Oliva
- Department of Trauma and Orthopaedics, “Tor Vergata” University, Rome, Italy
| | - N. Maffulli
- Department of Musculoskeletal Disorders, University of Salerno, School of Medicine, Salerno, Italy
| |
Collapse
|
15
|
Affiliation(s)
- R L Patel
- Department of Cardiothoracic Surgery, St Thomas' Hospital, London
| | | | | | | |
Collapse
|
16
|
Abstract
SummaryThe full potential use of technetium has not been achieved despite its ideal physical properties, dosimetry and availability because of the complex preparations required for 99mTc radiopharmaceuticals. One of the goals of our work is to develop techniques for the preparation of high-purity 99mTc compounds which can be easily prepared, ideally by adding pertechnetate to a prepared solution.The use of stannous ion as reducing agent for technetium makes it possible to obtain such one-step, high-purity products. All non-radioactive components can be premixed in a single vial before addition of the radioactive pertechnetate. No final pH adjustment, further chemical manipulation or purification is required.Procedures for two instantly labeled compounds have been developed to date: 99mTc DTPA and 99mTc HSA. The 99mTc DTPA is prepared by adding pertechnetate to a previously prepared solution of stannous ion and CaNa3 DTPA which has been stored at pH 4. The 99mTc HSA is prepared by adding pertechnetate to a solution of stannous ion and HSA. The parametric variations and analytical techniques involved in formulating these procedures are described. It appears that development of kits for other biologically interesting compounds may be possible using similar procedures.
Collapse
|
17
|
Srivastava SC, Fawwaz RA, Giacomini P, Ferrone S, Richards P, Hardy M, Alderson PO, Wang TST. A Comparison of the Cyclic Anhydride and Mixed Anhydride Methods for 111In-DTPA Chelation to Monoclonal Antibodies. Nuklearmedizin 2018. [DOI: 10.1055/s-0038-1624217] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
SummaryThe cyclic anhydride (CA) and the mixed anhydride (MA) of DTPA were synthesized and used to chelate 111In to an antimelanoma monoclonal antibody. The CA and MA methods showed mean labeling efficiencies of 25.7 and 20.5%, respectively (p = NS). The binding efficiency of labeled antibody to human melanoma cells in tissue culture also was similar (x̄ = 52 and 50%, respectively, p = NS), as was tumor uptake in nude mice at 96 hrs post-injection (16%-CA vs 12%-MA). The method required less complicated chemical syntheses, much less preparation time, and the product was stable over a much longer period. The results suggest that the CA method is preferable for bifunctional chelate labeling of monoclonal antibodies with 111In-DTPA.
Collapse
|
18
|
Black RJ, Robson JC, Goodman SM, Hoon E, Lai LYH, Simon LS, Harrison E, Neill L, Richards P, Nelsen LM, Nebesky JM, Mackie SL, Hill CL. A Patient-reported Outcome Measure for Effect of Glucocorticoid Therapy in Adults with Inflammatory Diseases Is Needed: Report from the OMERACT 2016 Special Interest Group. J Rheumatol 2017; 44:1754-1758. [PMID: 28365575 DOI: 10.3899/jrheum.161083] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 02/14/2017] [Indexed: 12/19/2022]
Abstract
OBJECTIVE The need for a standardized instrument to measure the effect of glucocorticoid (GC) therapy has been well documented in the literature. The aim of the first GC Special Interest Group was to define a research agenda around the development of a patient-reported outcome measure (PROM) in this area. METHODS The results of a background literature search and the preliminary results of a pilot survey and 2 qualitative studies were presented to facilitate the development of a research agenda. RESULTS It was agreed that there was a need for a data-driven PROM that identified both positive and negative effects of GC therapy to be used across all inflammatory indications for systemic GC use in adults. A research agenda was developed, consisting of further qualitative work to assess the effect of GC across different groups including various indications for GC use, different age groups, different dosages, and duration of treatment. CONCLUSION There was agreement on the need for a PROM in this area and a research agenda was set.
Collapse
Affiliation(s)
- Rachel J Black
- From the Discipline of Medicine, School of Public Health, The University of Adelaide; Rheumatology Unit, The Royal Adelaide Hospital, Adelaide; Rheumatology Unit, The Queen Elizabeth Hospital, Woodville, Australia; Faculty of Health and Applied Sciences, University of the West of England; University of Bristol, Bristol; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds; PMR & GCA UK North East, Kibblesworth; PMR and GCA Scotland, Berwickshire, Foulden, UK; Hospital for Special Surgery, New York, New York; SDG LLC, Cambridge, Massachusetts; Value Evidence and Outcomes, GlaxoSmithKline, Collegeville, Pennsylvania, USA; F. Hoffmann-Roche Ltd., Basel, Switzerland.
- R.J. Black, MBBS, PhD Candidate, Consultant Rheumatologist, Clinical Lecturer, Discipline of Medicine, The University of Adelaide, and Rheumatology Unit, The Royal Adelaide Hospital; J.C. Robson, MRCP, PhD, Consultant Senior Lecturer in Rheumatology, University of the West of England, and Honorary Senior Lecturer, University of Bristol, and Honorary Consultant, University Hospitals Bristol UK National Health Service Trust, and Faculty of Health and Applied Sciences, University of the West of England; S.M. Goodman, MD, Associate Professor of Clinical Medicine, Hospital for Special Surgery; E. Hoon, PhD, Arthritis SA Florey Research Fellow, School of Public Health, The University of Adelaide; L.Y. Lai, MSc, PhD Candidate, Board Certified Pharmacotherapy Specialist, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; L.S. Simon, MD, Principal, SDG LLC; E. Harrison, BSc (Hons Physiology), OMERACT Patient Research Partner, PMR and GCA UK North East; L. Neill, BSc (Hons Nat Phil), OMERACT Patient Research Partner, PMR and GCA Scotland; P. Richards, HNC (Business Studies), OMERACT Patient Research Partner, University of Bristol; L.M. Nelsen, MHS, Director, Patient Focused Outcomes, Value Evidence and Outcomes, GlaxoSmithKline; J.M. Nebesky, MD, Senior Medical Director, F. Hoffmann-La Roche Ltd.; S.L. Mackie, PhD, Associate Clinical Professor, Honorary Consultant Rheumatologist, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; C.L. Hill, MD, Clinical Professor, Consultant Rheumatologist, Discipline of Medicine, The University of Adelaide, and Rheumatology Unit, The Royal Adelaide Hospital, and Rheumatology Unit, The Queen Elizabeth Hospital.
| | - Joanna C Robson
- From the Discipline of Medicine, School of Public Health, The University of Adelaide; Rheumatology Unit, The Royal Adelaide Hospital, Adelaide; Rheumatology Unit, The Queen Elizabeth Hospital, Woodville, Australia; Faculty of Health and Applied Sciences, University of the West of England; University of Bristol, Bristol; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds; PMR & GCA UK North East, Kibblesworth; PMR and GCA Scotland, Berwickshire, Foulden, UK; Hospital for Special Surgery, New York, New York; SDG LLC, Cambridge, Massachusetts; Value Evidence and Outcomes, GlaxoSmithKline, Collegeville, Pennsylvania, USA; F. Hoffmann-Roche Ltd., Basel, Switzerland
- R.J. Black, MBBS, PhD Candidate, Consultant Rheumatologist, Clinical Lecturer, Discipline of Medicine, The University of Adelaide, and Rheumatology Unit, The Royal Adelaide Hospital; J.C. Robson, MRCP, PhD, Consultant Senior Lecturer in Rheumatology, University of the West of England, and Honorary Senior Lecturer, University of Bristol, and Honorary Consultant, University Hospitals Bristol UK National Health Service Trust, and Faculty of Health and Applied Sciences, University of the West of England; S.M. Goodman, MD, Associate Professor of Clinical Medicine, Hospital for Special Surgery; E. Hoon, PhD, Arthritis SA Florey Research Fellow, School of Public Health, The University of Adelaide; L.Y. Lai, MSc, PhD Candidate, Board Certified Pharmacotherapy Specialist, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; L.S. Simon, MD, Principal, SDG LLC; E. Harrison, BSc (Hons Physiology), OMERACT Patient Research Partner, PMR and GCA UK North East; L. Neill, BSc (Hons Nat Phil), OMERACT Patient Research Partner, PMR and GCA Scotland; P. Richards, HNC (Business Studies), OMERACT Patient Research Partner, University of Bristol; L.M. Nelsen, MHS, Director, Patient Focused Outcomes, Value Evidence and Outcomes, GlaxoSmithKline; J.M. Nebesky, MD, Senior Medical Director, F. Hoffmann-La Roche Ltd.; S.L. Mackie, PhD, Associate Clinical Professor, Honorary Consultant Rheumatologist, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; C.L. Hill, MD, Clinical Professor, Consultant Rheumatologist, Discipline of Medicine, The University of Adelaide, and Rheumatology Unit, The Royal Adelaide Hospital, and Rheumatology Unit, The Queen Elizabeth Hospital
| | - Susan M Goodman
- From the Discipline of Medicine, School of Public Health, The University of Adelaide; Rheumatology Unit, The Royal Adelaide Hospital, Adelaide; Rheumatology Unit, The Queen Elizabeth Hospital, Woodville, Australia; Faculty of Health and Applied Sciences, University of the West of England; University of Bristol, Bristol; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds; PMR & GCA UK North East, Kibblesworth; PMR and GCA Scotland, Berwickshire, Foulden, UK; Hospital for Special Surgery, New York, New York; SDG LLC, Cambridge, Massachusetts; Value Evidence and Outcomes, GlaxoSmithKline, Collegeville, Pennsylvania, USA; F. Hoffmann-Roche Ltd., Basel, Switzerland
- R.J. Black, MBBS, PhD Candidate, Consultant Rheumatologist, Clinical Lecturer, Discipline of Medicine, The University of Adelaide, and Rheumatology Unit, The Royal Adelaide Hospital; J.C. Robson, MRCP, PhD, Consultant Senior Lecturer in Rheumatology, University of the West of England, and Honorary Senior Lecturer, University of Bristol, and Honorary Consultant, University Hospitals Bristol UK National Health Service Trust, and Faculty of Health and Applied Sciences, University of the West of England; S.M. Goodman, MD, Associate Professor of Clinical Medicine, Hospital for Special Surgery; E. Hoon, PhD, Arthritis SA Florey Research Fellow, School of Public Health, The University of Adelaide; L.Y. Lai, MSc, PhD Candidate, Board Certified Pharmacotherapy Specialist, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; L.S. Simon, MD, Principal, SDG LLC; E. Harrison, BSc (Hons Physiology), OMERACT Patient Research Partner, PMR and GCA UK North East; L. Neill, BSc (Hons Nat Phil), OMERACT Patient Research Partner, PMR and GCA Scotland; P. Richards, HNC (Business Studies), OMERACT Patient Research Partner, University of Bristol; L.M. Nelsen, MHS, Director, Patient Focused Outcomes, Value Evidence and Outcomes, GlaxoSmithKline; J.M. Nebesky, MD, Senior Medical Director, F. Hoffmann-La Roche Ltd.; S.L. Mackie, PhD, Associate Clinical Professor, Honorary Consultant Rheumatologist, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; C.L. Hill, MD, Clinical Professor, Consultant Rheumatologist, Discipline of Medicine, The University of Adelaide, and Rheumatology Unit, The Royal Adelaide Hospital, and Rheumatology Unit, The Queen Elizabeth Hospital
| | - Elizabeth Hoon
- From the Discipline of Medicine, School of Public Health, The University of Adelaide; Rheumatology Unit, The Royal Adelaide Hospital, Adelaide; Rheumatology Unit, The Queen Elizabeth Hospital, Woodville, Australia; Faculty of Health and Applied Sciences, University of the West of England; University of Bristol, Bristol; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds; PMR & GCA UK North East, Kibblesworth; PMR and GCA Scotland, Berwickshire, Foulden, UK; Hospital for Special Surgery, New York, New York; SDG LLC, Cambridge, Massachusetts; Value Evidence and Outcomes, GlaxoSmithKline, Collegeville, Pennsylvania, USA; F. Hoffmann-Roche Ltd., Basel, Switzerland
- R.J. Black, MBBS, PhD Candidate, Consultant Rheumatologist, Clinical Lecturer, Discipline of Medicine, The University of Adelaide, and Rheumatology Unit, The Royal Adelaide Hospital; J.C. Robson, MRCP, PhD, Consultant Senior Lecturer in Rheumatology, University of the West of England, and Honorary Senior Lecturer, University of Bristol, and Honorary Consultant, University Hospitals Bristol UK National Health Service Trust, and Faculty of Health and Applied Sciences, University of the West of England; S.M. Goodman, MD, Associate Professor of Clinical Medicine, Hospital for Special Surgery; E. Hoon, PhD, Arthritis SA Florey Research Fellow, School of Public Health, The University of Adelaide; L.Y. Lai, MSc, PhD Candidate, Board Certified Pharmacotherapy Specialist, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; L.S. Simon, MD, Principal, SDG LLC; E. Harrison, BSc (Hons Physiology), OMERACT Patient Research Partner, PMR and GCA UK North East; L. Neill, BSc (Hons Nat Phil), OMERACT Patient Research Partner, PMR and GCA Scotland; P. Richards, HNC (Business Studies), OMERACT Patient Research Partner, University of Bristol; L.M. Nelsen, MHS, Director, Patient Focused Outcomes, Value Evidence and Outcomes, GlaxoSmithKline; J.M. Nebesky, MD, Senior Medical Director, F. Hoffmann-La Roche Ltd.; S.L. Mackie, PhD, Associate Clinical Professor, Honorary Consultant Rheumatologist, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; C.L. Hill, MD, Clinical Professor, Consultant Rheumatologist, Discipline of Medicine, The University of Adelaide, and Rheumatology Unit, The Royal Adelaide Hospital, and Rheumatology Unit, The Queen Elizabeth Hospital
| | - Lana Y H Lai
- From the Discipline of Medicine, School of Public Health, The University of Adelaide; Rheumatology Unit, The Royal Adelaide Hospital, Adelaide; Rheumatology Unit, The Queen Elizabeth Hospital, Woodville, Australia; Faculty of Health and Applied Sciences, University of the West of England; University of Bristol, Bristol; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds; PMR & GCA UK North East, Kibblesworth; PMR and GCA Scotland, Berwickshire, Foulden, UK; Hospital for Special Surgery, New York, New York; SDG LLC, Cambridge, Massachusetts; Value Evidence and Outcomes, GlaxoSmithKline, Collegeville, Pennsylvania, USA; F. Hoffmann-Roche Ltd., Basel, Switzerland
- R.J. Black, MBBS, PhD Candidate, Consultant Rheumatologist, Clinical Lecturer, Discipline of Medicine, The University of Adelaide, and Rheumatology Unit, The Royal Adelaide Hospital; J.C. Robson, MRCP, PhD, Consultant Senior Lecturer in Rheumatology, University of the West of England, and Honorary Senior Lecturer, University of Bristol, and Honorary Consultant, University Hospitals Bristol UK National Health Service Trust, and Faculty of Health and Applied Sciences, University of the West of England; S.M. Goodman, MD, Associate Professor of Clinical Medicine, Hospital for Special Surgery; E. Hoon, PhD, Arthritis SA Florey Research Fellow, School of Public Health, The University of Adelaide; L.Y. Lai, MSc, PhD Candidate, Board Certified Pharmacotherapy Specialist, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; L.S. Simon, MD, Principal, SDG LLC; E. Harrison, BSc (Hons Physiology), OMERACT Patient Research Partner, PMR and GCA UK North East; L. Neill, BSc (Hons Nat Phil), OMERACT Patient Research Partner, PMR and GCA Scotland; P. Richards, HNC (Business Studies), OMERACT Patient Research Partner, University of Bristol; L.M. Nelsen, MHS, Director, Patient Focused Outcomes, Value Evidence and Outcomes, GlaxoSmithKline; J.M. Nebesky, MD, Senior Medical Director, F. Hoffmann-La Roche Ltd.; S.L. Mackie, PhD, Associate Clinical Professor, Honorary Consultant Rheumatologist, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; C.L. Hill, MD, Clinical Professor, Consultant Rheumatologist, Discipline of Medicine, The University of Adelaide, and Rheumatology Unit, The Royal Adelaide Hospital, and Rheumatology Unit, The Queen Elizabeth Hospital
| | - Lee S Simon
- From the Discipline of Medicine, School of Public Health, The University of Adelaide; Rheumatology Unit, The Royal Adelaide Hospital, Adelaide; Rheumatology Unit, The Queen Elizabeth Hospital, Woodville, Australia; Faculty of Health and Applied Sciences, University of the West of England; University of Bristol, Bristol; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds; PMR & GCA UK North East, Kibblesworth; PMR and GCA Scotland, Berwickshire, Foulden, UK; Hospital for Special Surgery, New York, New York; SDG LLC, Cambridge, Massachusetts; Value Evidence and Outcomes, GlaxoSmithKline, Collegeville, Pennsylvania, USA; F. Hoffmann-Roche Ltd., Basel, Switzerland
- R.J. Black, MBBS, PhD Candidate, Consultant Rheumatologist, Clinical Lecturer, Discipline of Medicine, The University of Adelaide, and Rheumatology Unit, The Royal Adelaide Hospital; J.C. Robson, MRCP, PhD, Consultant Senior Lecturer in Rheumatology, University of the West of England, and Honorary Senior Lecturer, University of Bristol, and Honorary Consultant, University Hospitals Bristol UK National Health Service Trust, and Faculty of Health and Applied Sciences, University of the West of England; S.M. Goodman, MD, Associate Professor of Clinical Medicine, Hospital for Special Surgery; E. Hoon, PhD, Arthritis SA Florey Research Fellow, School of Public Health, The University of Adelaide; L.Y. Lai, MSc, PhD Candidate, Board Certified Pharmacotherapy Specialist, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; L.S. Simon, MD, Principal, SDG LLC; E. Harrison, BSc (Hons Physiology), OMERACT Patient Research Partner, PMR and GCA UK North East; L. Neill, BSc (Hons Nat Phil), OMERACT Patient Research Partner, PMR and GCA Scotland; P. Richards, HNC (Business Studies), OMERACT Patient Research Partner, University of Bristol; L.M. Nelsen, MHS, Director, Patient Focused Outcomes, Value Evidence and Outcomes, GlaxoSmithKline; J.M. Nebesky, MD, Senior Medical Director, F. Hoffmann-La Roche Ltd.; S.L. Mackie, PhD, Associate Clinical Professor, Honorary Consultant Rheumatologist, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; C.L. Hill, MD, Clinical Professor, Consultant Rheumatologist, Discipline of Medicine, The University of Adelaide, and Rheumatology Unit, The Royal Adelaide Hospital, and Rheumatology Unit, The Queen Elizabeth Hospital
| | - Eileen Harrison
- From the Discipline of Medicine, School of Public Health, The University of Adelaide; Rheumatology Unit, The Royal Adelaide Hospital, Adelaide; Rheumatology Unit, The Queen Elizabeth Hospital, Woodville, Australia; Faculty of Health and Applied Sciences, University of the West of England; University of Bristol, Bristol; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds; PMR & GCA UK North East, Kibblesworth; PMR and GCA Scotland, Berwickshire, Foulden, UK; Hospital for Special Surgery, New York, New York; SDG LLC, Cambridge, Massachusetts; Value Evidence and Outcomes, GlaxoSmithKline, Collegeville, Pennsylvania, USA; F. Hoffmann-Roche Ltd., Basel, Switzerland
- R.J. Black, MBBS, PhD Candidate, Consultant Rheumatologist, Clinical Lecturer, Discipline of Medicine, The University of Adelaide, and Rheumatology Unit, The Royal Adelaide Hospital; J.C. Robson, MRCP, PhD, Consultant Senior Lecturer in Rheumatology, University of the West of England, and Honorary Senior Lecturer, University of Bristol, and Honorary Consultant, University Hospitals Bristol UK National Health Service Trust, and Faculty of Health and Applied Sciences, University of the West of England; S.M. Goodman, MD, Associate Professor of Clinical Medicine, Hospital for Special Surgery; E. Hoon, PhD, Arthritis SA Florey Research Fellow, School of Public Health, The University of Adelaide; L.Y. Lai, MSc, PhD Candidate, Board Certified Pharmacotherapy Specialist, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; L.S. Simon, MD, Principal, SDG LLC; E. Harrison, BSc (Hons Physiology), OMERACT Patient Research Partner, PMR and GCA UK North East; L. Neill, BSc (Hons Nat Phil), OMERACT Patient Research Partner, PMR and GCA Scotland; P. Richards, HNC (Business Studies), OMERACT Patient Research Partner, University of Bristol; L.M. Nelsen, MHS, Director, Patient Focused Outcomes, Value Evidence and Outcomes, GlaxoSmithKline; J.M. Nebesky, MD, Senior Medical Director, F. Hoffmann-La Roche Ltd.; S.L. Mackie, PhD, Associate Clinical Professor, Honorary Consultant Rheumatologist, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; C.L. Hill, MD, Clinical Professor, Consultant Rheumatologist, Discipline of Medicine, The University of Adelaide, and Rheumatology Unit, The Royal Adelaide Hospital, and Rheumatology Unit, The Queen Elizabeth Hospital
| | - Lorna Neill
- From the Discipline of Medicine, School of Public Health, The University of Adelaide; Rheumatology Unit, The Royal Adelaide Hospital, Adelaide; Rheumatology Unit, The Queen Elizabeth Hospital, Woodville, Australia; Faculty of Health and Applied Sciences, University of the West of England; University of Bristol, Bristol; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds; PMR & GCA UK North East, Kibblesworth; PMR and GCA Scotland, Berwickshire, Foulden, UK; Hospital for Special Surgery, New York, New York; SDG LLC, Cambridge, Massachusetts; Value Evidence and Outcomes, GlaxoSmithKline, Collegeville, Pennsylvania, USA; F. Hoffmann-Roche Ltd., Basel, Switzerland
- R.J. Black, MBBS, PhD Candidate, Consultant Rheumatologist, Clinical Lecturer, Discipline of Medicine, The University of Adelaide, and Rheumatology Unit, The Royal Adelaide Hospital; J.C. Robson, MRCP, PhD, Consultant Senior Lecturer in Rheumatology, University of the West of England, and Honorary Senior Lecturer, University of Bristol, and Honorary Consultant, University Hospitals Bristol UK National Health Service Trust, and Faculty of Health and Applied Sciences, University of the West of England; S.M. Goodman, MD, Associate Professor of Clinical Medicine, Hospital for Special Surgery; E. Hoon, PhD, Arthritis SA Florey Research Fellow, School of Public Health, The University of Adelaide; L.Y. Lai, MSc, PhD Candidate, Board Certified Pharmacotherapy Specialist, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; L.S. Simon, MD, Principal, SDG LLC; E. Harrison, BSc (Hons Physiology), OMERACT Patient Research Partner, PMR and GCA UK North East; L. Neill, BSc (Hons Nat Phil), OMERACT Patient Research Partner, PMR and GCA Scotland; P. Richards, HNC (Business Studies), OMERACT Patient Research Partner, University of Bristol; L.M. Nelsen, MHS, Director, Patient Focused Outcomes, Value Evidence and Outcomes, GlaxoSmithKline; J.M. Nebesky, MD, Senior Medical Director, F. Hoffmann-La Roche Ltd.; S.L. Mackie, PhD, Associate Clinical Professor, Honorary Consultant Rheumatologist, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; C.L. Hill, MD, Clinical Professor, Consultant Rheumatologist, Discipline of Medicine, The University of Adelaide, and Rheumatology Unit, The Royal Adelaide Hospital, and Rheumatology Unit, The Queen Elizabeth Hospital
| | - Pam Richards
- From the Discipline of Medicine, School of Public Health, The University of Adelaide; Rheumatology Unit, The Royal Adelaide Hospital, Adelaide; Rheumatology Unit, The Queen Elizabeth Hospital, Woodville, Australia; Faculty of Health and Applied Sciences, University of the West of England; University of Bristol, Bristol; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds; PMR & GCA UK North East, Kibblesworth; PMR and GCA Scotland, Berwickshire, Foulden, UK; Hospital for Special Surgery, New York, New York; SDG LLC, Cambridge, Massachusetts; Value Evidence and Outcomes, GlaxoSmithKline, Collegeville, Pennsylvania, USA; F. Hoffmann-Roche Ltd., Basel, Switzerland
- R.J. Black, MBBS, PhD Candidate, Consultant Rheumatologist, Clinical Lecturer, Discipline of Medicine, The University of Adelaide, and Rheumatology Unit, The Royal Adelaide Hospital; J.C. Robson, MRCP, PhD, Consultant Senior Lecturer in Rheumatology, University of the West of England, and Honorary Senior Lecturer, University of Bristol, and Honorary Consultant, University Hospitals Bristol UK National Health Service Trust, and Faculty of Health and Applied Sciences, University of the West of England; S.M. Goodman, MD, Associate Professor of Clinical Medicine, Hospital for Special Surgery; E. Hoon, PhD, Arthritis SA Florey Research Fellow, School of Public Health, The University of Adelaide; L.Y. Lai, MSc, PhD Candidate, Board Certified Pharmacotherapy Specialist, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; L.S. Simon, MD, Principal, SDG LLC; E. Harrison, BSc (Hons Physiology), OMERACT Patient Research Partner, PMR and GCA UK North East; L. Neill, BSc (Hons Nat Phil), OMERACT Patient Research Partner, PMR and GCA Scotland; P. Richards, HNC (Business Studies), OMERACT Patient Research Partner, University of Bristol; L.M. Nelsen, MHS, Director, Patient Focused Outcomes, Value Evidence and Outcomes, GlaxoSmithKline; J.M. Nebesky, MD, Senior Medical Director, F. Hoffmann-La Roche Ltd.; S.L. Mackie, PhD, Associate Clinical Professor, Honorary Consultant Rheumatologist, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; C.L. Hill, MD, Clinical Professor, Consultant Rheumatologist, Discipline of Medicine, The University of Adelaide, and Rheumatology Unit, The Royal Adelaide Hospital, and Rheumatology Unit, The Queen Elizabeth Hospital
| | - Linda M Nelsen
- From the Discipline of Medicine, School of Public Health, The University of Adelaide; Rheumatology Unit, The Royal Adelaide Hospital, Adelaide; Rheumatology Unit, The Queen Elizabeth Hospital, Woodville, Australia; Faculty of Health and Applied Sciences, University of the West of England; University of Bristol, Bristol; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds; PMR & GCA UK North East, Kibblesworth; PMR and GCA Scotland, Berwickshire, Foulden, UK; Hospital for Special Surgery, New York, New York; SDG LLC, Cambridge, Massachusetts; Value Evidence and Outcomes, GlaxoSmithKline, Collegeville, Pennsylvania, USA; F. Hoffmann-Roche Ltd., Basel, Switzerland
- R.J. Black, MBBS, PhD Candidate, Consultant Rheumatologist, Clinical Lecturer, Discipline of Medicine, The University of Adelaide, and Rheumatology Unit, The Royal Adelaide Hospital; J.C. Robson, MRCP, PhD, Consultant Senior Lecturer in Rheumatology, University of the West of England, and Honorary Senior Lecturer, University of Bristol, and Honorary Consultant, University Hospitals Bristol UK National Health Service Trust, and Faculty of Health and Applied Sciences, University of the West of England; S.M. Goodman, MD, Associate Professor of Clinical Medicine, Hospital for Special Surgery; E. Hoon, PhD, Arthritis SA Florey Research Fellow, School of Public Health, The University of Adelaide; L.Y. Lai, MSc, PhD Candidate, Board Certified Pharmacotherapy Specialist, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; L.S. Simon, MD, Principal, SDG LLC; E. Harrison, BSc (Hons Physiology), OMERACT Patient Research Partner, PMR and GCA UK North East; L. Neill, BSc (Hons Nat Phil), OMERACT Patient Research Partner, PMR and GCA Scotland; P. Richards, HNC (Business Studies), OMERACT Patient Research Partner, University of Bristol; L.M. Nelsen, MHS, Director, Patient Focused Outcomes, Value Evidence and Outcomes, GlaxoSmithKline; J.M. Nebesky, MD, Senior Medical Director, F. Hoffmann-La Roche Ltd.; S.L. Mackie, PhD, Associate Clinical Professor, Honorary Consultant Rheumatologist, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; C.L. Hill, MD, Clinical Professor, Consultant Rheumatologist, Discipline of Medicine, The University of Adelaide, and Rheumatology Unit, The Royal Adelaide Hospital, and Rheumatology Unit, The Queen Elizabeth Hospital
| | - J Michael Nebesky
- From the Discipline of Medicine, School of Public Health, The University of Adelaide; Rheumatology Unit, The Royal Adelaide Hospital, Adelaide; Rheumatology Unit, The Queen Elizabeth Hospital, Woodville, Australia; Faculty of Health and Applied Sciences, University of the West of England; University of Bristol, Bristol; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds; PMR & GCA UK North East, Kibblesworth; PMR and GCA Scotland, Berwickshire, Foulden, UK; Hospital for Special Surgery, New York, New York; SDG LLC, Cambridge, Massachusetts; Value Evidence and Outcomes, GlaxoSmithKline, Collegeville, Pennsylvania, USA; F. Hoffmann-Roche Ltd., Basel, Switzerland
- R.J. Black, MBBS, PhD Candidate, Consultant Rheumatologist, Clinical Lecturer, Discipline of Medicine, The University of Adelaide, and Rheumatology Unit, The Royal Adelaide Hospital; J.C. Robson, MRCP, PhD, Consultant Senior Lecturer in Rheumatology, University of the West of England, and Honorary Senior Lecturer, University of Bristol, and Honorary Consultant, University Hospitals Bristol UK National Health Service Trust, and Faculty of Health and Applied Sciences, University of the West of England; S.M. Goodman, MD, Associate Professor of Clinical Medicine, Hospital for Special Surgery; E. Hoon, PhD, Arthritis SA Florey Research Fellow, School of Public Health, The University of Adelaide; L.Y. Lai, MSc, PhD Candidate, Board Certified Pharmacotherapy Specialist, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; L.S. Simon, MD, Principal, SDG LLC; E. Harrison, BSc (Hons Physiology), OMERACT Patient Research Partner, PMR and GCA UK North East; L. Neill, BSc (Hons Nat Phil), OMERACT Patient Research Partner, PMR and GCA Scotland; P. Richards, HNC (Business Studies), OMERACT Patient Research Partner, University of Bristol; L.M. Nelsen, MHS, Director, Patient Focused Outcomes, Value Evidence and Outcomes, GlaxoSmithKline; J.M. Nebesky, MD, Senior Medical Director, F. Hoffmann-La Roche Ltd.; S.L. Mackie, PhD, Associate Clinical Professor, Honorary Consultant Rheumatologist, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; C.L. Hill, MD, Clinical Professor, Consultant Rheumatologist, Discipline of Medicine, The University of Adelaide, and Rheumatology Unit, The Royal Adelaide Hospital, and Rheumatology Unit, The Queen Elizabeth Hospital
| | - Sarah L Mackie
- From the Discipline of Medicine, School of Public Health, The University of Adelaide; Rheumatology Unit, The Royal Adelaide Hospital, Adelaide; Rheumatology Unit, The Queen Elizabeth Hospital, Woodville, Australia; Faculty of Health and Applied Sciences, University of the West of England; University of Bristol, Bristol; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds; PMR & GCA UK North East, Kibblesworth; PMR and GCA Scotland, Berwickshire, Foulden, UK; Hospital for Special Surgery, New York, New York; SDG LLC, Cambridge, Massachusetts; Value Evidence and Outcomes, GlaxoSmithKline, Collegeville, Pennsylvania, USA; F. Hoffmann-Roche Ltd., Basel, Switzerland
- R.J. Black, MBBS, PhD Candidate, Consultant Rheumatologist, Clinical Lecturer, Discipline of Medicine, The University of Adelaide, and Rheumatology Unit, The Royal Adelaide Hospital; J.C. Robson, MRCP, PhD, Consultant Senior Lecturer in Rheumatology, University of the West of England, and Honorary Senior Lecturer, University of Bristol, and Honorary Consultant, University Hospitals Bristol UK National Health Service Trust, and Faculty of Health and Applied Sciences, University of the West of England; S.M. Goodman, MD, Associate Professor of Clinical Medicine, Hospital for Special Surgery; E. Hoon, PhD, Arthritis SA Florey Research Fellow, School of Public Health, The University of Adelaide; L.Y. Lai, MSc, PhD Candidate, Board Certified Pharmacotherapy Specialist, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; L.S. Simon, MD, Principal, SDG LLC; E. Harrison, BSc (Hons Physiology), OMERACT Patient Research Partner, PMR and GCA UK North East; L. Neill, BSc (Hons Nat Phil), OMERACT Patient Research Partner, PMR and GCA Scotland; P. Richards, HNC (Business Studies), OMERACT Patient Research Partner, University of Bristol; L.M. Nelsen, MHS, Director, Patient Focused Outcomes, Value Evidence and Outcomes, GlaxoSmithKline; J.M. Nebesky, MD, Senior Medical Director, F. Hoffmann-La Roche Ltd.; S.L. Mackie, PhD, Associate Clinical Professor, Honorary Consultant Rheumatologist, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; C.L. Hill, MD, Clinical Professor, Consultant Rheumatologist, Discipline of Medicine, The University of Adelaide, and Rheumatology Unit, The Royal Adelaide Hospital, and Rheumatology Unit, The Queen Elizabeth Hospital
| | - Catherine L Hill
- From the Discipline of Medicine, School of Public Health, The University of Adelaide; Rheumatology Unit, The Royal Adelaide Hospital, Adelaide; Rheumatology Unit, The Queen Elizabeth Hospital, Woodville, Australia; Faculty of Health and Applied Sciences, University of the West of England; University of Bristol, Bristol; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds; PMR & GCA UK North East, Kibblesworth; PMR and GCA Scotland, Berwickshire, Foulden, UK; Hospital for Special Surgery, New York, New York; SDG LLC, Cambridge, Massachusetts; Value Evidence and Outcomes, GlaxoSmithKline, Collegeville, Pennsylvania, USA; F. Hoffmann-Roche Ltd., Basel, Switzerland
- R.J. Black, MBBS, PhD Candidate, Consultant Rheumatologist, Clinical Lecturer, Discipline of Medicine, The University of Adelaide, and Rheumatology Unit, The Royal Adelaide Hospital; J.C. Robson, MRCP, PhD, Consultant Senior Lecturer in Rheumatology, University of the West of England, and Honorary Senior Lecturer, University of Bristol, and Honorary Consultant, University Hospitals Bristol UK National Health Service Trust, and Faculty of Health and Applied Sciences, University of the West of England; S.M. Goodman, MD, Associate Professor of Clinical Medicine, Hospital for Special Surgery; E. Hoon, PhD, Arthritis SA Florey Research Fellow, School of Public Health, The University of Adelaide; L.Y. Lai, MSc, PhD Candidate, Board Certified Pharmacotherapy Specialist, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; L.S. Simon, MD, Principal, SDG LLC; E. Harrison, BSc (Hons Physiology), OMERACT Patient Research Partner, PMR and GCA UK North East; L. Neill, BSc (Hons Nat Phil), OMERACT Patient Research Partner, PMR and GCA Scotland; P. Richards, HNC (Business Studies), OMERACT Patient Research Partner, University of Bristol; L.M. Nelsen, MHS, Director, Patient Focused Outcomes, Value Evidence and Outcomes, GlaxoSmithKline; J.M. Nebesky, MD, Senior Medical Director, F. Hoffmann-La Roche Ltd.; S.L. Mackie, PhD, Associate Clinical Professor, Honorary Consultant Rheumatologist, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; C.L. Hill, MD, Clinical Professor, Consultant Rheumatologist, Discipline of Medicine, The University of Adelaide, and Rheumatology Unit, The Royal Adelaide Hospital, and Rheumatology Unit, The Queen Elizabeth Hospital
| |
Collapse
|
19
|
Minnock P, McKee G, Kelly A, Carter SC, Menzies V, O'Sullivan D, Richards P, Ndosi M, van Eijk Hustings Y. Nursing sensitive outcomes in patients with rheumatoid arthritis: A systematic literature review. Int J Nurs Stud 2017; 77:115-129. [PMID: 29080437 DOI: 10.1016/j.ijnurstu.2017.09.005] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/24/2016] [Revised: 08/25/2017] [Accepted: 09/09/2017] [Indexed: 12/11/2022]
Abstract
BACKGROUND Although rheumatology nursing has been shown to be effective in managing patients with rheumatoid arthritis, patient outcomes sensitive to nursing interventions (nursing sensitive outcomes) have not been systematically studied. OBJECTIVES The objective of this study was to identify and delineate relevant patient outcomes measured in studies that reported nursing interventions in patients with rheumatoid arthritis. DESIGN A systematic search was conducted from 1990 to 2016. Inclusion criteria were (i) patients with rheumatoid arthritis, (ii) adult population age ≥16years, (iii) nurse as part of the care team or intervention delivery, (iv) primary research only, (v) English language, and (vi) quantitative studies with nursing sensitive outcomes. DATA SOURCES Medline, CINAHL, Ovid nursing, Cochrane library and PsycINFO databases were searched for relevant studies. REVIEW METHODS Using the predetermined inclusion/exclusion criteria, nine reviewers working in pairs assessed the eligibility of the identified studies based on titles and abstracts. Papers meeting the inclusion criteria were retrieved and full texts were further assessed. Critical Appraisal Skills Programme tools were used to assess the quality of the included studies. Data on nursing sensitive outcomes were extracted independently by two reviewers. The Outcome Measures in Rheumatology comprehensive conceptual framework for health was used to contextualise and present findings. RESULTS Of the 820 articles retrieved, 7 randomised controlled trials and 3 observational studies met the inclusion criteria. Seventeen nursing sensitive outcomes were identified (disease activity, clinical effects, pain, early morning stiffness duration, fatigue, patient safety issues, function, knowledge, patient satisfaction, confidence in care received, mental health status, self-efficacy, patient attitude/perception of ability to control arthritis, quality of life, health utility, health care resources, death). These fitted into 10 health intervention domains in keeping with the pre-specified conceptual framework for health: disease status, effectiveness, safety, function, knowledge, satisfaction, psychological status, quality of life, cost, death. A total of 59 measurement instruments were identified comprising patient reported outcome measures (n=31), and biologic measures and reports (n=28). CONCLUSIONS This review is notable in that it is the first to have identified, and reported, a set of multidimensional outcome measures that are sensitive to nursing interventions in rheumatology specifically. Further research is required to determine a core set of outcomes to be used in all rheumatology nursing intervention studies.
Collapse
Affiliation(s)
- Patricia Minnock
- Rheumatic Musculoskeletal Disease Unit, Our Lady's Hospice & Care Services, Harold's Cross, Dublin 6w, Ireland.
| | - Gabrielle McKee
- School of Nursing & Midwifery, Trinity College Dublin, Ireland
| | - Alexia Kelly
- St Vincent's Private Hospital Dublin, Ireland; St Vincent's University Hospital, Dublin, Ireland
| | - Sheree C Carter
- The University of Alabama, Capstone College of Nursing, Tuscaloosa, AL, USA
| | - Victoria Menzies
- Virginia Commonwealth University, School of Nursing, Richmond, VA, USA
| | | | - Pam Richards
- University of Bristol, Academic Rheumatology Bristol, Bristol, UK
| | - Mwidimi Ndosi
- Department of Nursing and Midwifery, University of the West of England, Bristol, UK
| | - Yvonne van Eijk Hustings
- Department of Clinical Epidemiology and Medical Technology Assessment, Department of Rheumatology, Maastricht University Medical Centre, Maastricht, The Netherlands
| |
Collapse
|
20
|
Janni W, Alba Conejo E, Bachelot T, Diab S, Gil-Gil M, Beck T, Ryvo L, López R, Tsai M, Esteva F, Zamora Aunon M, Kral Z, Ward P, Richards P, Pluard T, Sutradhar S, Miller M, Campone M. Duration of response and tumor shrinkage with first-line ribociclib + letrozole in postmenopausal women with HR+, HER2– ABC. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx365.008] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
21
|
Affiliation(s)
| | - P. Richards
- Brookhaven National Laboratory, Upton, New York
| | - L. Schiffer
- Brookhaven National Laboratory, Upton, New York
| |
Collapse
|
22
|
Richards P. I117. THE INVOLVEMENT OF PATIENTS AS STAKEHOLDERS IN THE OUTCOME MEASURES IN RHEUMATOID ARTHRITIS CLINICAL TRIALS. Rheumatology (Oxford) 2017. [DOI: 10.1093/rheumatology/kex060.117] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
23
|
O'Shaughnessy J, DeMichele A, Ma C, Richards P, Yardley DA, Wright G, Kalinsky K, Steis R, Diab S, Kennealey G, Geschwindt R, Jiang W, Rugo H. Abstract P4-22-04: A randomized, double-blind, phase 2 study of ruxolitinib (RUX) or placebo (PBO) in combination with capecitabine (CAPE) in patients (pts) with advanced HER2-negative breast cancer (ABC) and elevated C-reactive protein (CRP), a marker of systemic inflammation. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p4-22-04] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Systemic inflammation is associated with poor prognosis in pts with ABC. The JAK/STAT pathway is a key regulator of inflammatory signaling, associated with tumorigenesis, cell survival, and progression. We evaluated the efficacy and safety of RUX, a JAK1/JAK2 inhibitor, plus CAPE in pts with HER2-negative ABC and high systemic inflammation defined by the modified Glasgow Prognostic Score (mGPS). Methods: In this double-blind phase 2 trial, pts were randomized 1:1 to 21 day cycles of RUX+CAPE or PBO+CAPE: RUX 15 mg or PBO PO BID for 21 d; CAPE 1000 mg/m2 PO BID for 14 d. Key inclusion criteria were systemic inflammation by mGPS of 1 or 2 (ie, CRP >10 mg/L), ECOG performance status ≤2, ≤2 prior chemotherapy regimens, and no prior CAPE. The primary endpoint was overall survival (OS); key secondary endpoints were progression-free survival (PFS), objective response rate (ORR; complete [CR] + partial response [PR]) per RECIST v1.1, clinical benefit rate (CBR; CR + PR + stable disease for ≥6 mo), duration of response, and safety. Treatment differences in OS and PFS were analyzed by the log-rank test; HRs and CIs were analyzed by the Cox proportional hazards model. Results: Baseline characteristics were similar between pts randomized to RUX+CAPE (n=76) vs PBO+CAPE (n=73): mGPS status (1, 82.9% vs 83.6%), hormone receptor (HR) status (positive, 67.1% vs 63.0%), and number of prior chemotherapy regimens for ABC (0, 50.0% vs 50.7%; 1, 38.2% vs 34.2%; 2, 9.2% vs 13.7%). Median treatment durations were 85 d with RUX in the RUX+CAPE group and 65 d with PBO in the PBO+CAPE group. Median OS was 11.2 mo with RUX+CAPE vs 10.9 mo with PBO+CAPE (HR, 0.932; 95% CI, 0.59–1.46; P=0.762). Median OS was 6.1 mo with RUX+CAPE vs 5.5 mo with PBO+CAPE in HR-negative pts and 11.7 mo and 12.2 mo in HR-positive pts. Median PFS was 4.5 mo with RUX+CAPE and 2.5 mo with PBO+CAPE (HR, 0.737; 95% CI, 0.49–1.12; P=0.151). Median PFS was 2.1 mo with RUX+CAPE vs 2.2 mo with PBO+CAPE in HR-negative pts and 6.1 mo and 4.1 mo in HR-positive pts. ORRs were 28.9% and 13.7% (P=0.024) in the RUX+CAPE and PBO+CAPE arms, respectively. The CBRs were 13.2% and 6.8%, respectively (P=0.278). Worsening of hematologic toxicity was higher and rates of grade 3/4 palmar-plantar erythrodysethesia (PPE) were lower (1.4% vs 12.7%, respectively) with RUX+CAPE (Table).
Safety RUX+CAPE (n=71)PBO+CAPE (n=71)%All-GradeGrade 3/4All-GradeGrade 3/4Nonhematologic Adverse Event*Fatigue56.35.643.74.2Nausea54.98.549.35.6Diarrhea47.98.526.82.8PPE46.51.438.012.7Vomiting38.05.629.64.2Hypokalemia15.58.57.02.8Worsening of Hematologic Toxicity†Anemia80.323.956.37.0Lymphopenia40.815.545.112.7Neutropenia39.411.322.52.8Thrombocytopenia39.411.315.51.4*Most common all-grade (≥35%) or grade 3/4 (≥5%) events in the RUX+CAPE arm (safety group). †Laboratory abnormalities.
Conclusion: These data support the prognostic capabilities of the mGPS. The addition of RUX to CAPE for pts with ABC and high systemic inflammation was associated with an improved ORR compared with PBO+CAPE, but did not improve OS or PFS.
Citation Format: O'Shaughnessy J, DeMichele A, Ma C, Richards P, Yardley DA, Wright G, Kalinsky K, Steis R, Diab S, Kennealey G, Geschwindt R, Jiang W, Rugo H. A randomized, double-blind, phase 2 study of ruxolitinib (RUX) or placebo (PBO) in combination with capecitabine (CAPE) in patients (pts) with advanced HER2-negative breast cancer (ABC) and elevated C-reactive protein (CRP), a marker of systemic inflammation [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P4-22-04.
Collapse
Affiliation(s)
- J O'Shaughnessy
- Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, TX; University of Pennsylvania, Philadelphia, PA; Washington University School of Medicine, St Louis, MO; Oncology & Hematology Associates of Southwest Virginia, Inc, Salem, VA; Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville, TN; Florida Cancer Specialists, St Petersburg, FL; Columbia University Medical Center, New York, NY; Northside Hospital, Inc, Atlanta, GA; Rocky Mountain Cancer Centers, Aurora, CO; Incyte Corporation, Wilmington, DE; University of California, San Francisco, CA
| | - A DeMichele
- Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, TX; University of Pennsylvania, Philadelphia, PA; Washington University School of Medicine, St Louis, MO; Oncology & Hematology Associates of Southwest Virginia, Inc, Salem, VA; Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville, TN; Florida Cancer Specialists, St Petersburg, FL; Columbia University Medical Center, New York, NY; Northside Hospital, Inc, Atlanta, GA; Rocky Mountain Cancer Centers, Aurora, CO; Incyte Corporation, Wilmington, DE; University of California, San Francisco, CA
| | - C Ma
- Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, TX; University of Pennsylvania, Philadelphia, PA; Washington University School of Medicine, St Louis, MO; Oncology & Hematology Associates of Southwest Virginia, Inc, Salem, VA; Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville, TN; Florida Cancer Specialists, St Petersburg, FL; Columbia University Medical Center, New York, NY; Northside Hospital, Inc, Atlanta, GA; Rocky Mountain Cancer Centers, Aurora, CO; Incyte Corporation, Wilmington, DE; University of California, San Francisco, CA
| | - P Richards
- Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, TX; University of Pennsylvania, Philadelphia, PA; Washington University School of Medicine, St Louis, MO; Oncology & Hematology Associates of Southwest Virginia, Inc, Salem, VA; Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville, TN; Florida Cancer Specialists, St Petersburg, FL; Columbia University Medical Center, New York, NY; Northside Hospital, Inc, Atlanta, GA; Rocky Mountain Cancer Centers, Aurora, CO; Incyte Corporation, Wilmington, DE; University of California, San Francisco, CA
| | - DA Yardley
- Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, TX; University of Pennsylvania, Philadelphia, PA; Washington University School of Medicine, St Louis, MO; Oncology & Hematology Associates of Southwest Virginia, Inc, Salem, VA; Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville, TN; Florida Cancer Specialists, St Petersburg, FL; Columbia University Medical Center, New York, NY; Northside Hospital, Inc, Atlanta, GA; Rocky Mountain Cancer Centers, Aurora, CO; Incyte Corporation, Wilmington, DE; University of California, San Francisco, CA
| | - G Wright
- Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, TX; University of Pennsylvania, Philadelphia, PA; Washington University School of Medicine, St Louis, MO; Oncology & Hematology Associates of Southwest Virginia, Inc, Salem, VA; Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville, TN; Florida Cancer Specialists, St Petersburg, FL; Columbia University Medical Center, New York, NY; Northside Hospital, Inc, Atlanta, GA; Rocky Mountain Cancer Centers, Aurora, CO; Incyte Corporation, Wilmington, DE; University of California, San Francisco, CA
| | - K Kalinsky
- Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, TX; University of Pennsylvania, Philadelphia, PA; Washington University School of Medicine, St Louis, MO; Oncology & Hematology Associates of Southwest Virginia, Inc, Salem, VA; Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville, TN; Florida Cancer Specialists, St Petersburg, FL; Columbia University Medical Center, New York, NY; Northside Hospital, Inc, Atlanta, GA; Rocky Mountain Cancer Centers, Aurora, CO; Incyte Corporation, Wilmington, DE; University of California, San Francisco, CA
| | - R Steis
- Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, TX; University of Pennsylvania, Philadelphia, PA; Washington University School of Medicine, St Louis, MO; Oncology & Hematology Associates of Southwest Virginia, Inc, Salem, VA; Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville, TN; Florida Cancer Specialists, St Petersburg, FL; Columbia University Medical Center, New York, NY; Northside Hospital, Inc, Atlanta, GA; Rocky Mountain Cancer Centers, Aurora, CO; Incyte Corporation, Wilmington, DE; University of California, San Francisco, CA
| | - S Diab
- Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, TX; University of Pennsylvania, Philadelphia, PA; Washington University School of Medicine, St Louis, MO; Oncology & Hematology Associates of Southwest Virginia, Inc, Salem, VA; Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville, TN; Florida Cancer Specialists, St Petersburg, FL; Columbia University Medical Center, New York, NY; Northside Hospital, Inc, Atlanta, GA; Rocky Mountain Cancer Centers, Aurora, CO; Incyte Corporation, Wilmington, DE; University of California, San Francisco, CA
| | - G Kennealey
- Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, TX; University of Pennsylvania, Philadelphia, PA; Washington University School of Medicine, St Louis, MO; Oncology & Hematology Associates of Southwest Virginia, Inc, Salem, VA; Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville, TN; Florida Cancer Specialists, St Petersburg, FL; Columbia University Medical Center, New York, NY; Northside Hospital, Inc, Atlanta, GA; Rocky Mountain Cancer Centers, Aurora, CO; Incyte Corporation, Wilmington, DE; University of California, San Francisco, CA
| | - R Geschwindt
- Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, TX; University of Pennsylvania, Philadelphia, PA; Washington University School of Medicine, St Louis, MO; Oncology & Hematology Associates of Southwest Virginia, Inc, Salem, VA; Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville, TN; Florida Cancer Specialists, St Petersburg, FL; Columbia University Medical Center, New York, NY; Northside Hospital, Inc, Atlanta, GA; Rocky Mountain Cancer Centers, Aurora, CO; Incyte Corporation, Wilmington, DE; University of California, San Francisco, CA
| | - W Jiang
- Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, TX; University of Pennsylvania, Philadelphia, PA; Washington University School of Medicine, St Louis, MO; Oncology & Hematology Associates of Southwest Virginia, Inc, Salem, VA; Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville, TN; Florida Cancer Specialists, St Petersburg, FL; Columbia University Medical Center, New York, NY; Northside Hospital, Inc, Atlanta, GA; Rocky Mountain Cancer Centers, Aurora, CO; Incyte Corporation, Wilmington, DE; University of California, San Francisco, CA
| | - H Rugo
- Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, TX; University of Pennsylvania, Philadelphia, PA; Washington University School of Medicine, St Louis, MO; Oncology & Hematology Associates of Southwest Virginia, Inc, Salem, VA; Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville, TN; Florida Cancer Specialists, St Petersburg, FL; Columbia University Medical Center, New York, NY; Northside Hospital, Inc, Atlanta, GA; Rocky Mountain Cancer Centers, Aurora, CO; Incyte Corporation, Wilmington, DE; University of California, San Francisco, CA
| |
Collapse
|
24
|
Zaman O, Richards P, Ward S, Bortolami O, Collins K, Cheung K, Robinson T, Audisio R, Reed M, Wyld L. 83. Risk factors for surgical morbidity in older women with breast cancer: An interim analysis of the Bridging the Age Gap in Breast Cancer Study. Eur J Surg Oncol 2016. [DOI: 10.1016/j.ejso.2016.06.089] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
25
|
Scharfmann R, Didiesheim M, Richards P, Chandra V, Oshima M, Albagli O. Mass production of functional human pancreatic β-cells: why and how? Diabetes Obes Metab 2016; 18 Suppl 1:128-36. [PMID: 27615142 DOI: 10.1111/dom.12728] [Citation(s) in RCA: 26] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/08/2016] [Accepted: 05/17/2016] [Indexed: 12/17/2022]
Abstract
Diabetes (either type 1 or type 2) is due to insufficient functional β-cell mass. Research has, therefore, aimed to discover new ways to maintain or increase either β-cell mass or function. For this purpose, rodents have mainly been used as model systems and a large number of discoveries have been made. Meanwhile, although we have learned that rodent models represent powerful systems to model β-cell development, function and destruction, we realize that there are limitations when attempting to transfer the data to what is occurring in humans. Indeed, while human β-cells share many similarities with rodent β-cells, they also differ on a number of important parameters. In this context, developing ways to study human β-cell development, function and death represents an important challenge. This review will describe recent data on the development and use of convenient sources of human β-cells that should be useful tools to discover new ways to modulate functional β-cell mass in humans.
Collapse
Affiliation(s)
- R Scharfmann
- INSERM U1016, Université Paris-Descartes, Institut Cochin, Paris, France.
| | - M Didiesheim
- INSERM U1016, Université Paris-Descartes, Institut Cochin, Paris, France
| | - P Richards
- INSERM U1016, Université Paris-Descartes, Institut Cochin, Paris, France
| | - V Chandra
- INSERM U1016, Université Paris-Descartes, Institut Cochin, Paris, France
| | - M Oshima
- INSERM U1016, Université Paris-Descartes, Institut Cochin, Paris, France
| | - O Albagli
- INSERM U1016, Université Paris-Descartes, Institut Cochin, Paris, France
| |
Collapse
|
26
|
Smolen JS, Breedveld FC, Burmester GR, Bykerk V, Dougados M, Emery P, Kvien TK, Navarro-Compán MV, Oliver S, Schoels M, Scholte-Voshaar M, Stamm T, Stoffer M, Takeuchi T, Aletaha D, Andreu JL, Aringer M, Bergman M, Betteridge N, Bijlsma H, Burkhardt H, Cardiel M, Combe B, Durez P, Fonseca JE, Gibofsky A, Gomez-Reino JJ, Graninger W, Hannonen P, Haraoui B, Kouloumas M, Landewe R, Martin-Mola E, Nash P, Ostergaard M, Östör A, Richards P, Sokka-Isler T, Thorne C, Tzioufas AG, van Vollenhoven R, de Wit M, van der Heijde D. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis 2016; 75:3-15. [PMID: 25969430 PMCID: PMC4717393 DOI: 10.1136/annrheumdis-2015-207524] [Citation(s) in RCA: 941] [Impact Index Per Article: 117.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2015] [Revised: 04/10/2015] [Accepted: 04/13/2015] [Indexed: 01/23/2023]
Abstract
BACKGROUND Reaching the therapeutic target of remission or low-disease activity has improved outcomes in patients with rheumatoid arthritis (RA) significantly. The treat-to-target recommendations, formulated in 2010, have provided a basis for implementation of a strategic approach towards this therapeutic goal in routine clinical practice, but these recommendations need to be re-evaluated for appropriateness and practicability in the light of new insights. OBJECTIVE To update the 2010 treat-to-target recommendations based on systematic literature reviews (SLR) and expert opinion. METHODS A task force of rheumatologists, patients and a nurse specialist assessed the SLR results and evaluated the individual items of the 2010 recommendations accordingly, reformulating many of the items. These were subsequently discussed, amended and voted upon by >40 experts, including 5 patients, from various regions of the world. Levels of evidence, strengths of recommendations and levels of agreement were derived. RESULTS The update resulted in 4 overarching principles and 10 recommendations. The previous recommendations were partly adapted and their order changed as deemed appropriate in terms of importance in the view of the experts. The SLR had now provided also data for the effectiveness of targeting low-disease activity or remission in established rather than only early disease. The role of comorbidities, including their potential to preclude treatment intensification, was highlighted more strongly than before. The treatment aim was again defined as remission with low-disease activity being an alternative goal especially in patients with long-standing disease. Regular follow-up (every 1-3 months during active disease) with according therapeutic adaptations to reach the desired state was recommended. Follow-up examinations ought to employ composite measures of disease activity that include joint counts. Additional items provide further details for particular aspects of the disease, especially comorbidity and shared decision-making with the patient. Levels of evidence had increased for many items compared with the 2010 recommendations, and levels of agreement were very high for most of the individual recommendations (≥9/10). CONCLUSIONS The 4 overarching principles and 10 recommendations are based on stronger evidence than before and are supposed to inform patients, rheumatologists and other stakeholders about strategies to reach optimal outcomes of RA.
Collapse
Affiliation(s)
- Josef S Smolen
- Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria
- 2nd Department of Medicine, Hietzing Hospital, Vienna, Austria
| | - Ferdinand C Breedveld
- Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands
| | - Gerd R Burmester
- Department of Rheumatology, Clinical Immunology Free University and Humboldt University, Charité-University Medicine, Berlin, Germany
| | - Vivian Bykerk
- Division of Rheumatology, Hospital for Special Surgery, Weill Cornell Medical College, Cornell University, New York, USA
| | - Maxime Dougados
- Department of Rheumatology B, Cochin Hospital, René Descartes University, Paris, France
| | - Paul Emery
- Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Chapel Allerton Hospital,Leeds, UK
- NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, UK
| | - Tore K Kvien
- Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway
| | | | | | - Monika Schoels
- 2nd Department of Medicine, Hietzing Hospital, Vienna, Austria
| | - Marieke Scholte-Voshaar
- EULAR Standing Committee of People with Arthritis/Rheumatism in Europe (PARE), Zurich, Switzerland
| | - Tanja Stamm
- Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria
| | - Michaela Stoffer
- Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria
| | - Tsutomu Takeuchi
- Division of Rheumatology, Department of internal Medicine, Keio University School of Medicine, Tokyo, Japan
| | - Daniel Aletaha
- Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria
| | - Jose Louis Andreu
- Rheumatology Department, Hospital Universitario Puerta de Hierro-Majadahonda, Majadahonda, Spain
| | - Martin Aringer
- Department of Medicine III, University Medical Center TU Dresden, Dresden, Germany
| | - Martin Bergman
- Drexel University College of Medicine, Philadelphia, Pennsylvania, USA
| | - Neil Betteridge
- EULAR Standing Committee of People with Arthritis/Rheumatism in Europe (PARE), Zurich, Switzerland
| | - Hans Bijlsma
- Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, and VU University Medical Center, Amsterdam, The Netherlands
| | - Harald Burkhardt
- Division of Rheumatology, Department of Medicine, Johann-Wolfgang-Goethe University Frankfurt, German
| | - Mario Cardiel
- Centro de Investigación Clínica de Morelia, Morelia, Michoacán, Mexico
| | - Bernard Combe
- Service d'Immuno-Rhumatologie, Montpellier University, Lapeyronie Hospital, Montpellier, France
| | - Patrick Durez
- Pôle de Recherche en Rhumatologie, Institut de Recherche Experimentale et Clinique, Université Catholique de Louvain and Cliniques Universitaires Saint-Luc, Brussels, Belgium
| | - Joao Eurico Fonseca
- Rheumatology Research Unit, Instituto de de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal
- Rheumatology Department, Lisbon Academic Medical Centre, Lisbon, Portugal
| | - Alan Gibofsky
- Weill Medical College, Cornell University Hospital for Special Surgery, New York, USA
| | - Juan J Gomez-Reino
- Rheumatology Unit, Santiago University Clinical Hospital, Santiago de Compostela, Spain
| | | | - Pekka Hannonen
- Department of Medicine, Central Hospital, Jyväskylä, Finland
| | | | - Marios Kouloumas
- EULAR Standing Committee of People with Arthritis/Rheumatism in Europe (PARE), Zurich, Switzerland
| | - Robert Landewe
- Academic Medical Center, University of Amsterdam, Amsterdam, and Atrium Medical Center, Heerlen, The Netherlands
| | | | - Peter Nash
- University of Queensland, Brisbane, Queensland, Australia
| | - Mikkel Ostergaard
- Department of Clinical Medicine, Faculty of Health Sciences, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet and Glostrup Hospital, University of Copenhagen, Copenhagen, Denmark
| | - Andrew Östör
- Rheumatology Clinical Research Unit, School of Clinical Medicine, University of Cambridge, Addenbrooke's Hospital, Cambridge University Hospitals, NHS Foundation Trust, Cambridge, UK
| | - Pam Richards
- EULAR Standing Committee of People with Arthritis/Rheumatism in Europe (PARE), Zurich, Switzerland
| | | | - Carter Thorne
- Division of Rheumatology, Southlake Regional Health Centre, Newarket, Ontario, Canada
| | | | | | - Martinus de Wit
- EULAR Standing Committee of People with Arthritis/Rheumatism in Europe (PARE), Zurich, Switzerland
| | - Desirée van der Heijde
- Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands
- NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, UK
| |
Collapse
|
27
|
Morgan J, Richards P, Ward S, Francis M, Lawrence G, Collins K, Reed M, Wyld L. Case-mix analysis and variation in rates of non-surgical treatment of older women with operable breast cancer. Br J Surg 2015; 102:1056-63. [PMID: 26095684 DOI: 10.1002/bjs.9842] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2014] [Revised: 11/26/2014] [Accepted: 04/01/2015] [Indexed: 11/08/2022]
Abstract
BACKGROUND Non-surgical management of older women with oestrogen receptor (ER)-positive operable breast cancer is common in the UK, with up to 40 per cent of women aged over 70 years receiving primary endocrine therapy. Although this may be appropriate for frailer patients, for some it may result in treatment failure, contributing to the poor outcomes seen in this age group. Wide variation in the rates of non-operative management of breast cancer in older women exists across the UK. Case mix may explain some of this variation in practice. METHODS Data from two UK regional cancer registries were analysed to determine whether variation in treatment observed between 2002 and 2010 at hospital and clinician level persisted after adjustment for case mix. Expected case mix-adjusted surgery rates were derived by logistic regression using the variables age, proxy Charlson co-morbidity score, deprivation quintile, method of cancer detection, tumour size, stage, grade and node status. RESULTS Data on 17,129 women aged 70 years or more with ER-positive operable breast cancer were analysed. There was considerable variation in rates of surgery at both hospital and clinician level. Despite adjusting for case mix, this variation persisted at hospital level, although not at clinician level. CONCLUSION This study demonstrates variation in selection criteria for older women for operative treatment of early breast cancer, indicating that some older women may be undertreated or overtreated, and may partly explain the inferior disease outcomes in this age group. It emphasizes the urgent need for evidence-based guidelines for treatment selection criteria in older women with breast cancer.
Collapse
Affiliation(s)
- J Morgan
- Academic Unit of Surgical Oncology, University of Sheffield Medical School, Sheffield, UK
| | - P Richards
- Department of Health Economics and Decision Science, School for Health and Related Research, University of Sheffield, Sheffield, UK
| | - S Ward
- Department of Health Economics and Decision Science, School for Health and Related Research, University of Sheffield, Sheffield, UK
| | - M Francis
- Knowledge and Intelligence Team (West Midlands), Public Health England, Birmingham, UK
| | - G Lawrence
- Knowledge and Intelligence Team (West Midlands), Public Health England, Birmingham, UK
| | - K Collins
- Centre for Health and Social Care Research, Sheffield Hallam University, Sheffield, UK
| | - M Reed
- Academic Unit of Surgical Oncology, University of Sheffield Medical School, Sheffield, UK
| | - L Wyld
- Academic Unit of Surgical Oncology, University of Sheffield Medical School, Sheffield, UK
| |
Collapse
|
28
|
Kelly A, McKee G, van Eijk-Hustings Y, Ndosi M, O'Sullivan D, Menzies V, Carter S, Richards P, Minnock P. AB1213-HPR Nurse Sensitive Outcomes in Patients with Rheumatoid Arthritis (RA) – a Systematic Literature Review. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.4837] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
29
|
Lowe R, Cockshott Z, Greenwood R, Kirwan JR, Almeida C, Richards P, Hewlett S. Self-efficacy as an appraisal that moderates the coping-emotion relationship: associations among people with rheumatoid arthritis. Psychol Health 2014; 23:155-74. [PMID: 25160048 DOI: 10.1080/14768320601139160] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
Abstract
The way a coping strategy is expressed might depend on the nature of underlying efficacy expectations. For example, a cognitive coping strategy may have different content depending on efficacy beliefs underpinning the strategy's formulation and application. As such, self-efficacy (SE), as an appraisal, may moderate relationships between coping and outcomes: coping effects may differ depending on SE. This process was examined in 127 rheumatoid arthritis patients attending routine patient education/self-management programmes. Participants completed questionnaire measures of SE, coping, anxiety and depression at baseline and at 8 weeks follow-up. Regression analyses focused on coping and SE change variables, and their concurrent association with measures of change in anxiety and depression. Results highlighted contributions to these emotional variables from interactions between coping and SE. The nature of associations between coping and emotional outcomes was found to differ according to efficacy appraisals. This may have implications for clinical practice in that the adaptive significance of adjustment efforts may differ according to underlying SE.
Collapse
Affiliation(s)
- Rob Lowe
- a Department of Psychology , University of Wales , Swansea , UK
| | | | | | | | | | | | | |
Collapse
|
30
|
Astorri E, Tappuni A, Sutcliffe N, Richards P, Pitzalis C, Bombardieri M. THU0008 A Negative High-Resolution Salivary Gland Ultrasound is Highly Predictive of Negative Labial Gland Biopsy in Patients with SICCA Symptoms. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2014-eular.3114] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
31
|
Kirwan JR, Bartlett SJ, Beaton DE, Boers M, Bosworth A, Brooks PM, Choy E, de Wit M, Guillemin F, Hewlett S, Kvien TK, Landewé RB, Leong AL, Lyddiatt A, March L, May J, Montie PL, Nikaï E, Richards P, Voshaar MM, Smeets W, Strand V, Tugwell P, Gossec L. Updating the OMERACT Filter: Implications for Patient-reported Outcomes. J Rheumatol 2014; 41:1011-5. [DOI: 10.3899/jrheum.131312] [Citation(s) in RCA: 48] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Objective.At a previous Outcome Measures in Rheumatology (OMERACT) meeting, participants reflected on the underlying methods of patient-reported outcome (PRO) instrument development. The participants requested proposals for more explicit instrument development protocols that would contribute to an enhanced version of the “Truth” statement in the OMERACT Filter, a widely used guide for outcome validation. In the present OMERACT session, we explored to what extent these new Filter 2.0 proposals were practicable, feasible, and already being applied.Methods.Following overview presentations, discussion groups critically reviewed the extent to which case studies of current OMERACT Working Groups complied with or negated the proposed PRO development framework, whether these observations had a more general application, and what issues remained to be resolved.Results.Several aspects of PRO development were recognized as particularly important, and the need to directly involve patients at every stage of an iterative PRO development program was endorsed. This included recognition that patients contribute as partners in the research and not merely as subjects. Correct communication of concepts with the words used in questionnaires was central to their performance as measuring instruments, and ensuring this understanding crossed cultural and linguistic boundaries was important in international studies or comparisons.Conclusion.Participants recognized, endorsed, and were generally already putting into practice the principles of PRO development presented in the plenary session. Further work is needed on some existing instruments and on establishing widespread good practice for working in close collaboration with patients.
Collapse
|
32
|
Flurey CA, Morris M, Richards P, Hughes R, Hewlett S. It's like a juggling act: rheumatoid arthritis patient perspectives on daily life and flare while on current treatment regimes. Rheumatology (Oxford) 2013; 53:696-703. [PMID: 24357813 PMCID: PMC3970565 DOI: 10.1093/rheumatology/ket416] [Citation(s) in RCA: 68] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023] Open
Abstract
Objective. The objective of this study was to explore patients’ experiences of RA daily life while on modern treatments. Methods. The methods of this study comprised semi-structured interviews with 15 RA patients, analysed using inductive thematic analysis. Results. Four themes suggest patients experience life with RA along a continuum from RA in the background to the foreground of their lives, underpinned by constant actions to maintain balance. Living with RA in the background shows patients experience continuous, daily symptoms, which they mediate through micromanagement (mediating the impact of RA on daily life), while learning to incorporate RA into their identity (redefining me). RA moving into the foreground shows patients experience fluctuating symptoms (unwelcome reminders) that may or may not lead to a flare (trying to make sense of fluctuation). Dealing with RA in the foreground shows how patients attempt to manage RA flares (trying to regain control) and decide to seek medical help only after feeling they are losing control. Patients employ a stepped approach to self-management (mediation ladder) as symptoms increase, with seeking medical help often seen as the last resort. Patients seek to find a balance between managing their fluctuating RA and living their daily lives. Conclusion. Patients move back and forth along a continuum of RA in the background vs the foreground by balancing self-management of symptoms and everyday life. Clinicians need to appreciate that daily micromanagement is needed, even on current treatment regimes. Further research is needed to quantify the level and impact of daily symptoms and identify barriers and facilitators to seeking help.
Collapse
Affiliation(s)
- Caroline A Flurey
- Academic Rheumatology Unit, The Courtyard, Bristol Royal Infirmary, Bristol BS2 8HW.
| | | | | | | | | |
Collapse
|
33
|
Ramalingam S, Crawford J, Chang A, Manegold C, Perez-Soler R, Douillard JY, Thatcher N, Barlesi F, Owonikoko T, Wang Y, Pultar P, Zhu J, Malik R, Giaccone G, Della-Fiorentina S, Begbie S, Jennens R, Dass J, Pittman K, Ivanova N, Koynova T, Petrov P, Tomova A, Tzekova V, Couture F, Hirsh V, Burkes R, Sangha R, Ambrus M, Janaskova T, Musil J, Novotny J, Zatloukal P, Jakesova J, Klenha K, Roubec J, Vanasek J, Fayette J, Barlesi F, Bennouna-Louridi J, Chouaid C, Mazières J, Vallerand H, Robinet G, Souquet PJ, Spaeth D, Schott R, Lena H, Martinet Y, El Kouri C, Baize N, Scherpereel A, Molinier O, Fuchs F, Josten K, Manegold C, Marschner N, Schneller F, Overbeck T, Thomas M, von Pawel J, Reck M, Schuette W, Hagen V, Schneider CP, Georgoulias V, Varthalitis I, Zarogoulidis K, Syrigos K, Papandreou C, Bocskei C, Csanky E, Juhasz E, Losonczy G, Mark Z, Molnar I, Papai-Szekely Z, Tehenes S, Vinkler I, Almel S, Bakshi A, Bondarde S, Maru A, Pathak A, Pedapenki R, Prasad K, Prasad S, Kilara N, Gorijavolu D, Deshmukh C, John S, Sharma L, Amoroso D, Bajetta E, Bidoli P, Bonetti A, De Marinis F, Maio M, Passalacqua R, Cascinu S, Bearz A, Bitina M, Brize A, Purkalne G, Skrodele M, Baba A, Ratnavelu K, Saw M, Samson-Fernando M, Ladrera G, Jassem J, Koralewski P, Serwatowski P, Krzakowski M, Cebotaru C, Filip D, Ganea-Motan D, Ianuli C, Manolescu I, Udrea A, Burdaeva O, Byakhov M, Filippov A, Lazarev S, Mosin I, Orlov S, Udovitsa D, Khorinko A, Protsenko S, Chang A, Lim H, Tan Y, Tan E, Bastus Piulats R, Garcia-Foncillas J, Valdivia J, de Castro J, Domine Gomez M, Kim S, Lee JS, Kim H, Lee J, Shin S, Kim DW, Kim YC, Park K, Chang CS, Chang GC, Goan YG, Su WC, Tsai CM, Kuo HP, Benekli M, Demir G, Gokmen E, Sevinc A, Crawford J, Giaccone G, Haigentz M, Owonikoko T, Agarwal M, Pandit S, Araujo R, Vrindavanam N, Bonomi P, Berg A, Wade J, Bloom R, Amin B, Camidge R, Hill D, Rarick M, Flynn P, Klein L, Lo Russo K, Neubauer M, Richards P, Ruxer R, Savin M, Weckstein D, Rosenberg R, Whittaker T, Richards D, Berry W, Ottensmeier C, Dangoor A, Steele N, Summers Y, Rankin E, Rowley K, Giridharan S, Kristeleit H, Humber C, Taylor P. Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial). Ann Oncol 2013; 24:2875-80. [DOI: 10.1093/annonc/mdt371] [Citation(s) in RCA: 41] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
34
|
Habib AM, Richards P, Rogers GJ, Reimann F, Gribble FM. Co-localisation and secretion of glucagon-like peptide 1 and peptide YY from primary cultured human L cells. Diabetologia 2013; 56:1413-6. [PMID: 23519462 PMCID: PMC3648684 DOI: 10.1007/s00125-013-2887-z] [Citation(s) in RCA: 117] [Impact Index Per Article: 10.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/21/2012] [Accepted: 02/21/2013] [Indexed: 12/14/2022]
Abstract
AIMS/HYPOTHESIS Targeting the secretion of gut peptides such as glucagon-like peptide 1 (GLP-1) and peptide YY (PYY) is a strategy under development for the treatment of diabetes and obesity, aiming to mimic the beneficial alterations in intestinal physiology that follow gastric bypass surgery. In vitro systems are now well established for studying the mouse enteroendocrine system, but whether these accurately model the human gut remains unclear. The aim of this study was to establish and characterise human primary intestinal cultures as a model for assessing GLP-1 and PYY secretion in vitro. METHODS Fresh surgical biopsies of human colon were digested with collagenase to generate primary cultures from which GLP-1 and PYY secretion were assayed in response to test stimuli. GLP-1 and PYY co-localisation were assessed by flow cytometry and immunofluorescence microscopy. RESULTS GLP-1 and PYY were found localised in the same cells and the same secretory vesicles in human colonic tissue samples. GLP-1 release was increased to 2.6-fold the control value by forskolin + isobutylmethylxanthine (10 μmol/l each), 2.8-fold by phorbol myristate acetate (1 μmol/l) and 1.4-fold by linoleic acid (100 μmol/l). PYY release was increased to 2.0-, 1.8- and 1.3-fold by the same stimuli, respectively. Agonists of G-protein-coupled receptor (GPR)40/120 and G-protein-coupled bile acid receptor 1 (GPBAR1) each increased GLP-1 release to 1.5-fold, but a GPR119 agonist did not significantly stimulate secretion. CONCLUSIONS/INTERPRETATION Primary human colonic cultures provide an in vitro model for interrogating the human enteroendocrine system, and co-secrete GLP-1 and PYY. We found no evidence of PYY-specific cells not producing GLP-1. GLP-1 secretion was enhanced by small molecule agonists of GPR40/120 and GPBAR1.
Collapse
Affiliation(s)
- A. M. Habib
- Cambridge Institute for Medical Research, Addenbrooke’s Hospital Box 139, Hills Road, Cambridge, CB2 0XY UK
| | - P. Richards
- Cambridge Institute for Medical Research, Addenbrooke’s Hospital Box 139, Hills Road, Cambridge, CB2 0XY UK
| | - G. J. Rogers
- Cambridge Institute for Medical Research, Addenbrooke’s Hospital Box 139, Hills Road, Cambridge, CB2 0XY UK
| | - F. Reimann
- Cambridge Institute for Medical Research, Addenbrooke’s Hospital Box 139, Hills Road, Cambridge, CB2 0XY UK
| | - F. M. Gribble
- Cambridge Institute for Medical Research, Addenbrooke’s Hospital Box 139, Hills Road, Cambridge, CB2 0XY UK
| |
Collapse
|
35
|
Flurey CA, Morris M, Pollock J, Hughes R, Richards P, Hewlett S. AB0825-HPR “It’s like a juggling act“: ra patients experience a life of ‘fluctuating balances’. Ann Rheum Dis 2013. [DOI: 10.1136/annrheumdis-2013-eular.3147] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
36
|
Flurey C, Morris M, Pollock J, Hughes R, Richards P, Hewlett S. THU0470-HPR Will i waste your time? Delays in help-seeking for RA flares. Ann Rheum Dis 2013. [DOI: 10.1136/annrheumdis-2012-eular.2435] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
37
|
Flurey CA, Morris M, Pollock J, Hughes R, Richards P, Hewlett S. THU0579 Rheumatoid Arthritis Flares: Inflammatory or Avalanche? Ann Rheum Dis 2013. [DOI: 10.1136/annrheumdis-2013-eular.1107] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
38
|
Flurey C, Morris M, Pollock J, Hughes R, Richards P, Hewlett S. AB1427-HPR “it gets me down every single day”: are men with RA getting the support they need? Ann Rheum Dis 2013. [DOI: 10.1136/annrheumdis-2012-eular.1419] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
39
|
Cornell P, Trehane A, Thompson P, Rahmeh F, Greenwood M, Baqai TJ, Cambridge S, Shaikh M, Rooney M, Donnelly S, Tahir H, Ryan S, Kamath S, Hassell A, McCuish WJ, Bearne L, Mackenzie-Green B, Price E, Williamson L, Collins D, Tang E, Hayes J, McLoughlin YM, Chamberlain V, Campbell S, Shah P, McKenna F, Cornell P, Westlake S, Thompson P, Richards S, Homer D, Gould E, Empson B, Kemp P, Richards AG, Walker J, Taylor S, Bari SF, Alachkar M, Rajak R, Lawson T, O'Sullivan M, Samant S, Butt S, Gadsby K, Flurey CA, Morris M, Hughes R, Pollock J, Richards P, Hewlett S, Edwards KR, Rowe I, Sanders T, Dunn K, Konstantinou K, Hay E, Jones LE, Adams J, White P, Donovan-Hall M, Hislop K, Barbosa Boucas S, Nichols VP, Williamson EM, Toye F, Lamb SE, Rodham K, Gavin J, Watts L, Coulson N, Diver C, Avis M, Gupta A, Ryan SJ, Stangroom S, Pearce JM, Byrne J, Manning VL, Hurley M, Scott DL, Choy E, Bearne L, Taylor J, Morris M, Dures E, Hewlett S, Wilson A, Adams J, Larkin L, Kennedy N, Gallagher S, Fraser AD, Shrestha P, Batley M, Koduri G, Scott DL, Flurey CA, Morris M, Hughes R, Pollock J, Richards P, Hewlett S, Kumar K, Raza K, Nightingale P, Horne R, Chapman S, Greenfield S, Gill P, Ferguson AM, Ibrahim F, Scott DL, Lempp H, Tierney M, Fraser A, Kennedy N, Barbosa Boucas S, Hislop K, Dziedzic K, Arden N, Burridge J, Hammond A, Stokes M, Lewis M, Gooberman-Hill R, Coales K, Adams J, Nutland H, Dean A, Laxminarayan R, Gates L, Bowen C, Arden N, Hermsen L, Terwee CB, Leone SS, vd Zwaard B, Smalbrugge M, Dekker J, vd Horst H, Wilkie R, Ferguson AM, Nicky Thomas V, Lempp H, Cope A, Scott DL, Simpson C, Weinman J, Agarwal S, Kirkham B, Patel A, Ibrahim F, Barn R, Brandon M, Rafferty D, Sturrock R, Turner D, Woodburn J, Rafferty D, Paul L, Marshall R, Gill J, McInnes I, Roderick Porter D, Woodburn J, Hennessy K, Woodburn J, Steultjens M, Siddle HJ, Hodgson RJ, Hensor EM, Grainger AJ, Redmond A, Wakefield RJ, Helliwell PS, Hammond A, Rayner J, Law RJ, Breslin A, Kraus A, Maddison P, Thom JM, Newcombe LW, Woodburn J, Porter D, Saunders S, McCarey D, Gupta M, Turner D, McGavin L, Freeburn R, Crilly A, Lockhart JC, Ferrell WR, Goodyear C, Ledingham J, Waterman T, Berkin L, Nicolaou M, Watson P, Lillicrap M, Birrell F, Mooney J, Merkel PA, Poland F, Spalding N, Grayson P, Leduc R, Shereff D, Richesson R, Watts RA, Roussou E, Thapper M, Bateman J, Allen M, Kidd J, Parsons N, Davies D, Watt KA, Scally MD, Bosworth A, Wilkinson K, Collins S, Jacklin CB, Ball SK, Grosart R, Marks J, Litwic AE, Sriranganathan MK, Mukherjee S, Khurshid MA, Matthews SM, Hall A, Sheeran T, Baskar S, Muether M, Mackenzie-Green B, Hetherington A, Wickrematilake G, Williamson L, Daniels LE, Gwynne CE, Khan A, Lawson T, Clunie G, Stephenson S, Gaffney K, Belsey J, Harvey NC, Clarke-Harris R, Murray R, Costello P, Garrett E, Holbrook J, Teh AL, Wong J, Dogra S, Barton S, Davies L, Inskip H, Hanson M, Gluckman P, Cooper C, Godfrey K, Lillycrop K, Anderton T, Clarke S, Rao Chaganti S, Viner N, Seymour R, Edwards MH, Parsons C, Ward K, Thompson J, Prentice A, Dennison E, Cooper C, Clark E, Cumming M, Morrison L, Gould VC, Tobias J, Holroyd CR, Winder N, Osmond C, Fall C, Barker D, Ring S, Lawlor D, Tobias J, Davey Smith G, Cooper C, Harvey NC, Toms TE, Afreedi S, Salt K, Roskell S, Passey K, Price T, Venkatachalam S, Sheeran T, Davies R, Southwood TR, Kearsley-Fleet L, Hyrich KL, Kingsbury D, Quartier P, Patel G, Arora V, Kupper H, Mozaffarian N, Kearsley-Fleet L, Baildam E, Beresford MW, Davies R, Foster HE, Mowbray K, Southwood TR, Thomson W, Hyrich KL, Saunders E, Baildam E, Chieng A, Davidson J, Foster H, Gardner-Medwin J, Wedderburn L, Thomson W, Hyrich K, McErlane F, Beresford M, Baildam E, Chieng SE, Davidson J, Foster HE, Gardner-Medwin J, Lunt M, Wedderburn L, Thomson W, Hyrich K, Rooney M, Finnegan S, Gibson DS, Borg FA, Bale PJ, Armon K, Cavelle A, Foster HE, McDonagh J, Bale PJ, Armon K, Wu Q, Pesenacker AM, Stansfield A, King D, Barge D, Abinun M, Foster HE, Wedderburn L, Stanley K, Morrissey D, Parsons S, Kuttikat A, Shenker N, Garrood T, Medley S, Ferguson AM, Keeling D, Duffort P, Irving K, Goulston L, Culliford D, Coakley P, Taylor P, Hart D, Spector T, Hakim A, Arden N, Mian A, Garrood T, Magan T, Chaudhary M, Lazic S, Sofat N, Thomas MJ, Moore A, Roddy E, Peat G, Rees F, Lanyon P, Jordan N, Chaib A, Sangle S, Tungekar F, Sabharwal T, Abbs I, Khamashta M, D'Cruz D, Dzifa Dey I, Isenberg DA, Chin CW, Cheung C, Ng M, Gao F, Qiong Huang F, Thao Le T, Yong Fong K, San Tan R, Yin Wong T, Julian T, Parker B, Al-Husain A, Yvonne Alexander M, Bruce I, Jordan N, Abbs I, D'cruz D, McDonald G, Miguel L, Hall C, Isenberg DA, Magee A, Butters T, Jury E, Yee CS, Toescu V, Hickman R, Leung MH, Situnayake D, Bowman S, Gordon C, Yee CS, Toescu V, Hickman R, Leung MH, Situnayake D, Bowman S, Gordon C, Lazarus MN, Isenberg DA, Ehrenstein M, Carter LM, Isenberg DA, Ehrenstein MR, Chanchlani N, Gayed M, Yee CS, Gordon C, Ball E, Rooney M, Bell A, Reynolds JA, Ray DW, O'Neill T, Alexander Y, Bruce I, Sutton EJ, Watson KD, Isenberg D, Rahman A, Gordon C, Yee CS, Lanyon P, Jayne D, Akil M, D'Cruz D, Khamashta M, Lutalo P, Erb N, Prabu A, Edwards CJ, Youssef H, McHugh N, Vital E, Amft N, Griffiths B, Teh LS, Zoma A, Bruce I, Durrani M, Jordan N, Sangle S, D'Cruz D, Pericleous C, Ruiz-Limon P, Romay-Penabad Z, Carrera-Marin A, Garza-Garcia A, Murfitt L, Driscoll PC, Giles IP, Ioannou Y, Rahman A, Pierangeli SS, Ripoll VM, Lambrianides A, Heywood WE, Ioannou J, Giles IP, Rahman A, Stevens C, Dures E, Morris M, Knowles S, Hewlett S, Marshall R, Reddy V, Croca S, Gerona D, De La Torre Ortega I, Isenberg DA, Leandro M, Cambridge G, Reddy V, Cambridge G, Isenberg DA, Glennie M, Cragg M, Leandro M, Croca SC, Isenberg DA, Giles I, Ioannou Y, Rahman A, Croca SC, Isenberg DA, Giles I, Ioannou Y, Rahman A, Artim Esen B, Pericleous C, MacKie I, Ioannou Y, Rahman A, Isenberg DA, Giles I, Skeoch S, Haque S, Pemberton P, Bruce I. BHPR: Audit and Clinical Evaluation * 103. Dental Health in Children and Young Adults with Inflammatory Arthritis: Access to Dental Care. Rheumatology (Oxford) 2013. [DOI: 10.1093/rheumatology/ket196] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
40
|
Parker HE, Adriaenssens A, Rogers G, Richards P, Koepsell H, Reimann F, Gribble FM. Predominant role of active versus facilitative glucose transport for glucagon-like peptide-1 secretion. Diabetologia 2012; 55:2445-55. [PMID: 22638549 PMCID: PMC3411305 DOI: 10.1007/s00125-012-2585-2] [Citation(s) in RCA: 140] [Impact Index Per Article: 11.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/07/2012] [Accepted: 04/20/2012] [Indexed: 12/13/2022]
Abstract
AIMS/HYPOTHESIS Several glucose-sensing pathways have been implicated in glucose-triggered secretion of glucagon-like peptide-1 (GLP-1) from intestinal L cells. One involves glucose metabolism and closure of ATP-sensitive K(+) channels, and another exploits the electrogenic nature of Na(+)-coupled glucose transporters (SGLTs). This study aimed to elucidate the role of these distinct mechanisms in glucose-stimulated GLP-1 secretion. METHODS Glucose uptake into L cells (either GLUTag cells or cells in primary cultures, using a new transgenic mouse model combining proglucagon promoter-driven Cre recombinase with a ROSA26tdRFP reporter) was monitored with the FLII(12)Pglu-700 μδ6 glucose sensor. Effects of pharmacological and genetic interference with SGLT1 or facilitative glucose transport (GLUT) on intracellular glucose accumulation and metabolism (measured by NAD(P)H autofluorescence), cytosolic Ca(2+) (monitored with Fura2) and GLP-1 secretion (assayed by ELISA) were assessed. RESULTS L cell glucose uptake was dominated by GLUT-mediated transport, being abolished by phloretin but not phloridzin. NAD(P)H autofluorescence was glucose dependent and enhanced by a glucokinase activator. In GLUTag cells, but not primary L cells, phloretin partially impaired glucose-dependent secretion, and suppressed an amplifying effect of glucose under depolarising high K(+) conditions. The key importance of SGLT1 in GLUTag and primary cells was evident from the impairment of secretion by phloridzin or Sglt1 knockdown and failure of glucose to trigger cytosolic Ca(2+) elevation in primary L cells from Sglt1 knockout mice. CONCLUSIONS/INTERPRETATION SGLT1 acts as the luminal glucose sensor in L cells, but intracellular glucose concentrations are largely determined by GLUT activity. Although L cell glucose metabolism depends partially on glucokinase activity, this plays only a minor role in glucose-stimulated GLP-1 secretion.
Collapse
Affiliation(s)
- H. E. Parker
- Cambridge Institute for Medical Research, Wellcome Trust/MRC Building, Addenbrooke’s Hospital, Box 139, Hills Road, Cambridge, CB2 0XY UK
| | - A. Adriaenssens
- Cambridge Institute for Medical Research, Wellcome Trust/MRC Building, Addenbrooke’s Hospital, Box 139, Hills Road, Cambridge, CB2 0XY UK
| | - G. Rogers
- Cambridge Institute for Medical Research, Wellcome Trust/MRC Building, Addenbrooke’s Hospital, Box 139, Hills Road, Cambridge, CB2 0XY UK
| | - P. Richards
- Cambridge Institute for Medical Research, Wellcome Trust/MRC Building, Addenbrooke’s Hospital, Box 139, Hills Road, Cambridge, CB2 0XY UK
| | - H. Koepsell
- Institute of Anatomy and Cell Biology, University of Würzburg, Würzburg, Germany
| | - F. Reimann
- Cambridge Institute for Medical Research, Wellcome Trust/MRC Building, Addenbrooke’s Hospital, Box 139, Hills Road, Cambridge, CB2 0XY UK
| | - F. M. Gribble
- Cambridge Institute for Medical Research, Wellcome Trust/MRC Building, Addenbrooke’s Hospital, Box 139, Hills Road, Cambridge, CB2 0XY UK
| |
Collapse
|
41
|
Gauchotte-Lindsay C, Richards P, McGregor L, Thomas R, Kalin R. A one-step method for priority compounds of concern in tar from former industrial sites: Trimethylsilyl derivatisation with comprehensive two-dimensional gas chromatography. J Chromatogr A 2012; 1253:154-63. [DOI: 10.1016/j.chroma.2012.06.093] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2012] [Revised: 06/28/2012] [Accepted: 06/29/2012] [Indexed: 10/28/2022]
|
42
|
Szawarski P, Tam EW, Richards P. Stroke at high altitude. Hong Kong Med J 2012; 18:262. [PMID: 22665696] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/01/2023] Open
|
43
|
Harris C, Remedios D, Aptowitzer T, Keat A, Hamilton L, Guile G, Belkhiri A, Newman D, Toms A, Macgregor A, Gaffney K, Morton L, Jones GT, MacDonald AG, Downham C, Macfarlane GJ, Tillett W, Jadon D, Wallis D, Costa L, Waldron N, Griffith N, Cavill C, Korendowych E, de Vries C, McHugh N, Iaremenko O, Fedkov D, Emery P, Baeten D, Sieper J, Braun J, van der Heijde D, McInnes I, Van Laar J, Landewe R, Wordsworth BP, Wollenhaupt J, Kellner H, Paramarta I, Bertolino A, Wright AM, Hueber W, Sofat N, Smee C, Hermansson M, Wajed J, Sanyal K, Kiely P, Howard M, Howe FA, Barrick TR, Abraham AM, Pearce MS, Mann KD, Francis RM, Birrell F, Carr A, Macleod I, Ng WF, Kavanaugh A, van der Heijde D, Chattopadhyay C, Gladman D, Mease P, McInnes I, Krueger G, Xu W, Goldstein N, Beutler A, Van Laar J, Baraliakos X, Braun J, Laurent DD, Baeten D, van der Heijde D, Sieper J, Emery P, McInnes I, Landewe R, Wordsworth BP, Wollenhaupt J, Kellner H, Wright AM, Gsteiger S, Hueber W, Conaghan PG, Peterfy CG, DiCarlo J, Olech E, Alberts AR, Alper JA, Devenport J, Anisfeld AM, Troum OM, Cooper P, Gimpel M, Deakin G, Jameson K, Godtschailk M, Gadola S, Stokes M, Cooper C, Gordon C, Kalunian K, Petri M, Strand V, Kilgallen B, Barry A, Wallace D, Flurey CA, Morris M, Pollock J, Hughes R, Richards P, Hewlett S. Oral abstracts 1: Spondyloarthropathies * O1. Detecting axial spondyloarthritis amongst primary care back pain referrals. Rheumatology (Oxford) 2012. [DOI: 10.1093/rheumatology/kes118] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
44
|
Backhouse MR, Vinall KA, Redmond A, Helliwell P, Keenan AM, Dale RM, Thomas A, Aronson D, Turner-Cobb J, Sengupta R, France B, Hill I, Flurey CA, Morris M, Pollock J, Hughes R, Richards P, Hewlett S, Ryan S, Lille K, Adams J, Haq I, McArthur M, Goodacre L, Birt L, Wilson O, Kirwan J, Dures E, Quest E, Hewlett S, Rajak R, Thomas T, Lawson T, Petford S, Hale E, Kitas GD, Ryan S, Gooberman-Hill R, Jinks C, Dziedzic K, Boucas SB, Hislop K, Rhodes C, Adams J, Ali F, Jinks C, Ong BN, Backhouse MR, White D, Hensor E, Keenan AM, Helliwell P, Redmond A, Ferguson AM, Douiri A, Scott DL, Lempp H, Halls S, Law RJ, Jones J, Markland D, Maddison P, Thom J, Law RJ, Thom JM, Maddison P, Breslin A, Kraus A, Gordhan C, Dennis S, Connor J, Chowdhary B, Lottay N, Juneja P, Bacon PA, Isaacs D, Jack J, Keller M, Tibble J, Haq I, Hammond A, Gill R, Tyson S, Tennant A, Nordenskiold U, Pease EE, Pease CT, Trehane A, Rahmeh F, Cornell P, Westlake SL, Rose K, Alber CF, Watson L, Stratton R, Lazarus M, McNeilly NE, Waterfield J, Hurley M, Greenwood J, Clayton AM, Lynch M, Clewes A, Dawson J, Abernethy V, Griffiths AE, Chamberlain VA, McLoughlin Y, Campbell S, Hayes J, Moffat C, McKenna F, Shah P, Rajak R, Williams A, Rhys-Dillon C, Goodfellow R, Martin JC, Rajak R, Bari F, Hughes G, Thomas E, Baker S, Collins D, Price E, Williamson L, Dunkley L, Youll MJ, Rodziewicz M, Reynolds JA, Berry J, Pavey C, Hyrich K, Gorodkin R, Wilkinson K, Bruce I, Barton A, Silman A, Ho P, Cornell T, Westlake SL, Richards S, Holmes A, Parker S, Smith H, Briggs N, Arthanari S, Nisar M, Thwaites C, Ryan S, Kamath S, Price S, Robinson SM, Walker D, Coop H, Al-Allaf W, Baker S, Williamson L, Price E, Collins D, Charleton RC, Griffiths B, Edwards EA, Partlett R, Martin K, Tarzi M, Panthakalam S, Freeman T, Ainley L, Turner M, Hughes L, Russell B, Jenkins S, Done J, Young A, Jones T, Gaywood IC, Pande I, Pradere MJ, Bhaduri M, Smith A, Cook H, Abraham S, Ngcozana T, Denton CP, Parker L, Black CM, Ong V, Thompson N, White C, Duddy M, Jobanputra P, Bacon P, Smith J, Richardson A, Giancola G, Soh V, Spencer S, Greenhalgh A, Hanson M, De Lord D, Lloyd M, Wong H, Wren D, Grover B, Hall J, Neville C, Alton P, Kelly S, Bombardieri M, Humby F, Ng N, Di Cicco M, Hands R, Epis O, Filer A, Buckley C, McInnes I, Taylor P, Pitzalis C, Freeston J, Conaghan P, Grainger A, O'Connor PJ, Evans R, Emery P, Hodgson R, Emery P, Fleischmann R, Han C, van der Heijde D, Conaghan P, Xu W, Hsia E, Kavanaugh A, Gladman D, Chattopadhyay C, Beutler A, Han C, Zayat AS, Conaghan P, Freeston J, Hensor E, Ellegard K, Terslev L, Emery P, Wakefield RJ, Ciurtin C, Leandro M, Dey D, Nandagudi A, Giles I, Shipley M, Morris V, Ioannou J, Ehrenstein M, Sen D, Chan M, Quinlan TM, Brophy R, Mewar D, Patel D, Wilby MJ, Pellegrini V, Eyes B, Crooks D, Anderson M, Ball E, McKeeman H, Burns J, Yau WH, Moore O, Foo J, Benson C, Patterson C, Wright G, Taggart A, Drew S, Tanner L, Sanyal K, Bourke BE, Lloyd M, Alston C, Baqai C, Chard M, Sandhu V, Neville C, Jordan K, Munns C, Zouita L, Shattles W, Davies U, Makadsi R, Griffith S, Kiely PD, Ciurtin C, Dimofte I, Dabu M, Dabu B, Dobarro D, Schreiber BE, Warrell C, Handler C, Coghlan G, Denton C, Ishorari J, Bunn C, Beynon H, Denton CP, Stratton R, George Malal JJ, Boton-Maggs B, Leung A, Farewell D, Choy E, Gullick NJ, Young A, Choy EH, Scott DL, Wincup C, Fisher B, Charles P, Taylor P, Gullick NJ, Pollard LC, Kirkham BW, Scott DL, Ma MH, Ramanujan S, Cavet G, Haney D, Kingsley GH, Scott D, Cope A, Singh A, Wilson J, Isaacs A, Wing C, McLaughlin M, Penn H, Genovese MC, Sebba A, Rubbert-Roth A, Scali J, Zilberstein M, Thompson L, Van Vollenhoven R, De Benedetti F, Brunner H, Allen R, Brown D, Chaitow J, Pardeo M, Espada G, Flato B, Horneff G, Devlin C, Kenwright A, Schneider R, Woo P, Martini A, Lovell D, Ruperto N, John H, Hale ED, Treharne GJ, Kitas GD, Carroll D, Mercer L, Low A, Galloway J, Watson K, Lunt M, Symmons D, Hyrich K, Low A, Mercer L, Galloway J, Davies R, Watson K, Lunt M, Dixon W, Hyrich K, Symmons D, Balarajah S, Sandhu A, Ariyo M, Rankin E, Sandoo A, van Zanten JJV, Toms TE, Carroll D, Kitas GD, Sandoo A, Smith JP, Kitas GD, Malik S, Toberty E, Thalayasingam N, Hamilton J, Kelly C, Puntis D, Malik S, Hamilton J, Saravanan V, Rynne M, Heycock C, Kelly C, Rajak R, Goodfellow R, Rhys-Dillon C, Winter R, Wardle P, Martin JC, Toms T, Sandoo A, Smith J, Cadman S, Nightingale P, Kitas G, Alhusain AZ, Verstappen SM, Mirjafari H, Lunt M, Charlton-Menys V, Bunn D, Symmons D, Durrington P, Bruce I, Cooney JK, Thom JM, Moore JP, Lemmey A, Jones JG, Maddison PJ, Ahmad YA, Ahmed TJ, Leone F, Kiely PD, Browne HK, Rhys-Dillon C, Wig S, Chevance A, Moore T, Manning J, Vail A, Herrick AL, Derrett-Smith E, Hoyles R, Moinzadeh P, Chighizola C, Khan K, Ong V, Abraham D, Denton CP, Schreiber BE, Dobarro D, Warrell CE, Handler C, Denton CP, Coghlan G, Sykes R, Muir L, Ennis H, Herrick AL, Shiwen X, Thompson K, Khan K, Liu S, Denton CP, Leask A, Abraham DJ, Strickland G, Pauling J, Betteridge Z, Dunphy J, Owen P, McHugh N, Abignano G, Cuomo G, Buch MH, Rosenberg WM, Valentini G, Emery P, Del Galdo F, Jenkins J, Pauling JD, McHugh N, Khan K, Shiwen X, Abraham D, Denton CP, Ong V, Moinzadeh P, Howell K, Ong V, Nihtyanova S, Denton CP, Moinzadeh P, Fonseca C, Khan K, Abraham D, Ong V, Denton CP, Malaviya AP, Hadjinicolaou AV, Nisar MK, Ruddlesden M, Furlong A, Baker S, Hall FC, Hadjinicolaou AV, Malaviya AP, Nisar MK, Ruddlesden M, Raut-Roy D, Furlong A, Baker S, Hall FC, Peluso R, Dario Di Minno MN, Iervolino S, Costa L, Atteno M, Lofrano M, Soscia E, Castiglione F, Foglia F, Scarpa R, Wallis D, Thomas A, Hill I, France B, Sengupta R, Dougados M, Keystone E, Heckaman M, Mease P, Landewe R, Nguyen D, Heckaman M, Mease P, Winfield RA, Dyke C, Clemence M, Mackay K, Haywood KL, Packham J, Jordan KP, Davies H, Brophy S, Irvine E, Cooksey R, Dennis MS, Siebert S, Kingsley GH, Ibrahim F, Scott DL, Kavanaugh A, McInnes I, Chattopadhyay C, Krueger G, Gladman D, Beutler A, Gathany T, Mudivarthy S, Mack M, Tandon N, Han C, Mease P, McInnes I, Sieper J, Braun J, Emery P, van der Heijde D, Isaacs J, Dahmen G, Wollenhaupt J, Schulze-Koops H, Gsteiger S, Bertolino A, Hueber W, Tak PP, Cohen CJ, Karaderi T, Pointon JJ, Wordsworth BP, Cooksey R, Davies H, Dennis MS, Siebert S, Brophy S, Keidel S, Pointon JJ, Farrar C, Karaderi T, Appleton LH, Wordsworth BP, Adshead R, Tahir H, Greenwood M, Donnelly SP, Wajed J, Kirkham B. BHPR research: qualitative * 1. Complex reasoning determines patients' perception of outcome following foot surgery in rheumatoid arhtritis. Rheumatology (Oxford) 2012. [DOI: 10.1093/rheumatology/kes110] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
45
|
McMorrow RCN, Windsor JS, Hart ND, Richards P, Rodway GW, Ahuja VY, O’Dwyer MJ, Mythen MG, Grocott MPW. Closed and open breathing circuit function in healthy volunteers during exercise at Mount Everest base camp (5300 m). Anaesthesia 2012; 67:875-80. [DOI: 10.1111/j.1365-2044.2012.07152.x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
46
|
Ryman TK, Wallace A, Mihigo R, Richards P, Schlanger K, Cappelier K, Ndiaye S, Modjirom N, Tounkara B, Grant G, Anya B, Kiawi EC, Ochieng C, Kone S, Tesfaye H, Trayner N, Watkins M, Luman ET. Community and Health Worker Perceptions and Preferences Regarding Integration of Other Health Services With Routine Vaccinations: Four Case Studies. J Infect Dis 2012; 205 Suppl 1:S49-55. [DOI: 10.1093/infdis/jir796] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
47
|
Yardley DA, Hart L, Bosserman L, Saleh MN, Waterhouse DM, Richards P, Hagan MK, DeSilvio ML, Mahoney JM, Nagarwala Y. P1-12-10: Phase II Study Evaluating Lapatinib (L) in Combination with Albumin Bound Paclitaxel (ab-Pac) in Women Who Have Received 0–1 Chemotherapy Regimen for HER2 Overexpressing (HER2+) Metastatic Breast Cancer (MBC). Cancer Res 2011. [DOI: 10.1158/0008-5472.sabcs11-p1-12-10] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: L, a dual kinase inhibitor of epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor-2 (HER2), approved for the treatment of HER2+ MBC in combination with capecitabine following progression after trastuzumab, anthracycline, and taxane. L in combination with chemotherapy has significantly improved progression free survival in patients (pts) with HER2+ MBC. Ab-Pac is a cremophor free, albumin-bound paclitaxel approved for use in pts with MBC demonstrating superior efficacy and safety when compared to other taxanes.
Methods: Phase II study (LPT111111) evaluated the efficacy and safety of L in combination with ab-Pac in 60 pts with histologically confirmed stage IV HER2+ (IHC 3+/FISH+) invasive MBC. Pts received 0–1 prior chemotherapeutic regimen in the metastatic setting and no prior treatment with L. Prior taxane therapy permitted provided this was > 12 months prior to study entry, LVEF>50%, peripheral neuropathy < 2, prior CNS mets permitted, and prior endocrine therapy permitted. Pts received ab-Pac (125 mg/m2 IV on Days 1, 8, 15, q28 days) plus L (1250 mg daily). Planned safety analysis of the first 5 pts prompted a protocol amendment with a 20% dose reduction for both agents due to Grade (G) 3 neutropenia and diarrhea. Subsequent pts received ab-Pac (100 mg/m2 IV on Day 1, 8, 15, q28 days) in combination with L (1000 mg daily). Pts with SD or a response continued L alone until progression. Response assessments performed every 2 cycles. The primary endpoint was overall response rate (ORR) and secondary endpoints were progression-free survival (PFS), time to response, duration of response and overall survival (OS).
Results: Here we present the final analysis of all subjects receiving at least 6 months of protocol therapy. Median age is 56 years; 45 pts (75%) received treatment as 1st line therapy and 15 (25%) as 2nd line; 57% hormone receptor positive and 43% negative; 42% received trastuzumab and 40% received a taxane in either (neo) adjuvant or metastatic setting. After a median of 5.6 months, 7% pts had a complete response, 47% a partial response and 17% had stable disease, the ORR was 53% [95% CI: 41% to 66%]. The median time to response was 7.8 wks [95% CI: 7.4 to 8.1] with a median duration of response of 48.7 wks [95% CI: 31.7 to 57.1]. The median PFS was 39.7 wks [95% CI: 34.1 to 63.9]. Duration of exposure to ab-Pac; 48% received less than 6 cycles, 30% received 6 cycles and 22% received greater than 6 cycles. Table 1 shows the most common G ≥2 treatment-related toxicities.
Two fatal adverse events; one pt with a h/o arrhythmia experienced sudden death of presumed cardiac origin and the other subject with h/o COPD, hypertension and uncontrolled diabetes experienced acute renal failure. No G 3/4 elevation in LFTs observed.
Conclusions: L 1000 mg with ab-Pac 100 mg/m2 IV on Day 1, 8, 15, q28 day is feasible with manageable and predictable toxicity. The ORR of 53% compares favorably with other HER2 based combinations in this setting and warrants further exploration.
Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P1-12-10.
Collapse
Affiliation(s)
- DA Yardley
- 1Sarah Cannon Research Institute; Tennessee Oncology, PLLC; Florida Cancer Specialists; Willshire Oncology Medical Group; Georgia Cancer Specialists; Oncology & Hematology Care, Inc.; Virginia Cancer Care; Oncology & Hematology Associates of SW; GlaxoSmithKline, Collegeville, PA
| | - L Hart
- 1Sarah Cannon Research Institute; Tennessee Oncology, PLLC; Florida Cancer Specialists; Willshire Oncology Medical Group; Georgia Cancer Specialists; Oncology & Hematology Care, Inc.; Virginia Cancer Care; Oncology & Hematology Associates of SW; GlaxoSmithKline, Collegeville, PA
| | - L Bosserman
- 1Sarah Cannon Research Institute; Tennessee Oncology, PLLC; Florida Cancer Specialists; Willshire Oncology Medical Group; Georgia Cancer Specialists; Oncology & Hematology Care, Inc.; Virginia Cancer Care; Oncology & Hematology Associates of SW; GlaxoSmithKline, Collegeville, PA
| | - MN Saleh
- 1Sarah Cannon Research Institute; Tennessee Oncology, PLLC; Florida Cancer Specialists; Willshire Oncology Medical Group; Georgia Cancer Specialists; Oncology & Hematology Care, Inc.; Virginia Cancer Care; Oncology & Hematology Associates of SW; GlaxoSmithKline, Collegeville, PA
| | - DM Waterhouse
- 1Sarah Cannon Research Institute; Tennessee Oncology, PLLC; Florida Cancer Specialists; Willshire Oncology Medical Group; Georgia Cancer Specialists; Oncology & Hematology Care, Inc.; Virginia Cancer Care; Oncology & Hematology Associates of SW; GlaxoSmithKline, Collegeville, PA
| | - P Richards
- 1Sarah Cannon Research Institute; Tennessee Oncology, PLLC; Florida Cancer Specialists; Willshire Oncology Medical Group; Georgia Cancer Specialists; Oncology & Hematology Care, Inc.; Virginia Cancer Care; Oncology & Hematology Associates of SW; GlaxoSmithKline, Collegeville, PA
| | - MK Hagan
- 1Sarah Cannon Research Institute; Tennessee Oncology, PLLC; Florida Cancer Specialists; Willshire Oncology Medical Group; Georgia Cancer Specialists; Oncology & Hematology Care, Inc.; Virginia Cancer Care; Oncology & Hematology Associates of SW; GlaxoSmithKline, Collegeville, PA
| | - ML DeSilvio
- 1Sarah Cannon Research Institute; Tennessee Oncology, PLLC; Florida Cancer Specialists; Willshire Oncology Medical Group; Georgia Cancer Specialists; Oncology & Hematology Care, Inc.; Virginia Cancer Care; Oncology & Hematology Associates of SW; GlaxoSmithKline, Collegeville, PA
| | - JM Mahoney
- 1Sarah Cannon Research Institute; Tennessee Oncology, PLLC; Florida Cancer Specialists; Willshire Oncology Medical Group; Georgia Cancer Specialists; Oncology & Hematology Care, Inc.; Virginia Cancer Care; Oncology & Hematology Associates of SW; GlaxoSmithKline, Collegeville, PA
| | - Y Nagarwala
- 1Sarah Cannon Research Institute; Tennessee Oncology, PLLC; Florida Cancer Specialists; Willshire Oncology Medical Group; Georgia Cancer Specialists; Oncology & Hematology Care, Inc.; Virginia Cancer Care; Oncology & Hematology Associates of SW; GlaxoSmithKline, Collegeville, PA
| |
Collapse
|
48
|
Richards P. Experiencing family-centred care. Nurs N Z 2011; 17:3-4. [PMID: 22096816] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
|
49
|
Sanderson T, Hewlett S, Richards P, Morris M, Calnan M. Utilizing Qualitative Data from Nominal Groups: Exploring the Influences on Treatment Outcome Prioritization with Rheumatoid Arthritis Patients. J Health Psychol 2011; 17:132-42. [PMID: 21708868 DOI: 10.1177/1359105311410758] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
The nominal group technique generates quantitative data through a process of experts ranking items of interest. This article focuses on the additional collection of qualitative data from nominal groups with rheumatoid arthritis (RA) patients, used to explore the influences on prioritizing treatment outcomes. Across all groups, the top five outcomes with the highest importance scores were identified as: pain; joint damage; fatigue; activities of daily living; and mobility. Qualitative findings showed that the personal impact of RA influenced decisions on how to rank specific outcomes through four domains: disease impact; adaptation to illness; external resources and stressors; and social expectations.
Collapse
|
50
|
Ahmad M, Liu W, Lund M, Moran M, Richards P, Wu D, Chen Z, Deng J, Nath R. SU-E-T-485: Clinical Evaluation of Inverse Planning Models and IMRT Delivery Systems in the Framework of AAPM TG-119 Protocol. Med Phys 2011. [DOI: 10.1118/1.3612438] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|